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จลนศาสตรของการสรางสารแปรรูป C6G จาก Michaelis-Menten หรือ Substrate inhibition ไป
เปน Sigmoidal โดยการเพ่ิมข้ึนของคาพารามิเตอร Km (หรือ S50) โดยประมาณ 4.8-7.7 เทา ขอมูลนี้
อาจสันนิษฐานไดวาวาโปรอิคเอซิดจับกับ effector site ของเอนไซมซ่ึงมีผลตอจลนศาสตรของ
ปฏิกิริยากลูคิวโรนิเดชันของยาโคเดอีนท่ีซับซอนข้ึน 
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ABSTRACT 
  Since COD (codeine) is eliminated primarily via glucuronidation, factors that 
alter COD glucuronide formation potentially affect either the proportion of the dose converted to 
the pharmacologically active metabolite morphine or COD concentration in plasma. Thus, in vitro 
– in vivo extrapolation (IV-IVE) approaches were utilized to identify potential drug-drug 
interactions (DDIs) arising from inhibition of COD glucuronidation in humans. Initial studies 
characterized the kinetics of COD 6-glucuronide (C6G) formation by human liver microsome 
(HLM), and demonstrated an 88% reduction in Km (0.29 vs. 2.32 mM) for incubations performed 
in the presence of 2% bovine serum albumin (BSA). Of 13 recombinant UGT enzymes screened 
for COD glucuronidation activity, only UGT2B4 and UGT2B7 exhibited activity. The respective 
S50 values (0.32 and 0.27 mM) generated in the presence of BSA were comparable to the mean 
Km observed in HLM. Known inhibitors of UGT2B7 activity in vitro or in vivo were investigated 
for inhibition of C6G formation by HLM. Inhibition screening identified potential DDIs with 
fluconazole, ketamine, and ketoconazole. Ki values generated for fluconazole (202 μM), ketamine 
(3.51 μM), and ketoconazole (0.66 μM) predicted 1.60, 1.10, and 2.97-fold increases, 
respectively in the AUC ratio for COD in vivo. DDIs of COD with fluconazole and ketoconazole, 
but not ketamine potentially affect the COD analgesia, either intensity or duration and COD 
toxicity. In addition, this work showed a complex kinetic interaction between COD and valproic 
acid in both the absence and presence of BSA. Addition of valproic acid changed the kinetics of 
C6G formation from the Michaelis-Menten or Substrate inhibition to Sigmoidal kinetics with 
increasing of Km (or S50) values by approximately 4.8- to 7.7-fold. This data is further assumed 
  vi
that valproic acid binds to a distinct effector site of enzyme, which results in the complex COD 
glucuronidation kinetics.    
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CHAPTER 1 
INTRODUCTIONS 
1.1 Background and rationale 
The opioid codeine (COD) is one of the most widely used drugs worldwide. 
COD is employed extensively in the treatment of mild to moderate pain, either alone or in 
combination with other analgesics. Furthermore, COD is used as an antitussive and for the 
treatment of diarrhea. It is generally accepted that COD analgesia arises from cytochrome P450 
(CYP) 2D6 catalyzed O-demethylation to form morphine (Somogyi et al., 2007). Approximately 
4 to 10% of a COD dose is converted to morphine in CYP2D6 extensive and ultrarapid 
metabolizers (Chen et al., 1991; Yue et al., 1991; Kirchheiner et al., 2007). Other elimination 
pathways include glucuronidation, N-demethylation and renal clearance of unchanged drug. Of 
these, glucuronidation, to form COD-6-glucuronide (C6G), is the dominant metabolic pathway, 
accounting for 80-85% of the COD dose recovered in urine (Yue et al., 1991). 
Accumulating evidence indicates that the relative formation of morphine plays a 
pivotal role in COD response. In particular, variability in COD O-demethylation due to genetic 
polymorphism of CYP2D6 is known to influence both analgesia and the occurrence of morphine-
related adverse effects. In relation to  adverse effects, individuals who are  ultrarapid metabolisers 
(UMs) of CYP2D6 have on average 50% higher plasma concentrations of morphine than 
extensive metabolisers (EMs), which results in  a higher incidence of central nervous system 
(CNS) depression (Gasche et al., 2004; Kirchheiner et al., 2007; Samogyi et al., 2007). 
Additionally, a relationship between maternal COD use and neonatal toxicity has been reported. 
Breastfed infants of mothers who are CYP2D6 UMs are at increased risk of potentially life-
threatening CNS depression (Madadi et al., 2009). Although there is no evidence to confirm a 
shift to minor pathways, especially conversion to morphine due to inhibition of COD 
glucuronidation, the amount of COD available for other pathways may be increased. Since 
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glucuronidation is the dominant route of COD metabolism, changes in C6G formation will 
potentially affect the proportion of the dose metabolized via the O-demethylation pathway and 
hence the intensity and duration of pharmacological response. However, factors that influence 
COD glucuronidation in humans are poorly understood. Furthermore, serious adverse effects may 
arise from COD toxicity. In this regard, six fatalities have been reported from poisonings with 
COD. These deaths showed that a high COD concentration in plasma (> 0.4 mg/L of free COD 
concentration and > 2 mg/L of total COD concentration) may be sufficient to cause death in the 
absence of any other contributing factors (Gerostamoulos et al., 1996). 
It has been reported that COD 6-glucuronidation is catalyzed by UDP-
glucuronosyltransferase (UGT)2B7, with a possible contribution of UGT2B4 (Coffman et al., 
1998; Court et al., 2003). UGT2B7 is arguably the most important drug metabolizing UGT 
enzyme in humans (Miners et al., 2010). Apart from COD, UGT2B7 also glucuronidates other 
opioids (e.g. morphine, naloxone), many non-steroidal anti-inflammatory agents (viz. ketoprofen, 
ibuprofen, diclofenac, and naxoprofen), valproic acid (VPA), and zidovudine (AZT). Among 
these, morphine and AZT are commonly used drugs that could potentially serve as UGT2B7 
probes. A relatively common coding region polymorphism, UGT2B7*2 (His268Tyr), appears not 
to affect the glucuronidation of opioids, including COD (Bhasker et al., 2000; Court et al., 2003). 
Compelling evidence linking other UGT2B7 variants and opioid disposition and 
response is similarly lacking (Thorn et al., 2009). In contrast, data from both in vitro and in vivo 
studies indicate that inhibition of the metabolism of UGT2B7 substrates may result in significant 
drug-drug interactions (DDIs), with reduced clearance via glucuronidation. For example, DDIs in 
vivo have been reported between fluconazole (FLZ) and AZT. Administration of FLZ in a 
therapeutic dose (400 mg/day) decreased the apparent clearance of AZT by 47% corresponding to 
a 1.92-fold increase in the mean area under the plasma concentration–time curve (AUC) of AZT 
in patients infected with human immunodeficiency virus (Sahai et al., 1994). Consistent with in 
vitro studies, FLZ, ketamine (KTM), ketoconazole (KTZ), and VPA have been shown to inhibit 
in vitro probe substrates for UGT2B7. An inhibitor constant (Ki) for FLZ inhibition of AZT 
glucuronidation by human liver microsomes (HLM) was 1133 μM and reduced to 145 μM in the 
absence and presence of bovine serum albumin (BSA), respectively (Uchaipichat et al., 2006a), 
whereas the respective concentrations which caused 50% inhibition (IC50) reported by Trapnell et 
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al. (1998) were 163 μM (FLZ) and 693 μM (VPA). Similar to AZT glucuronidation, the Ki value 
of KTM inhibition on morphine-6-glucuronide formation in the presence and absence of 2% BSA 
were 35 μM and 5 μM, respectively (Miners JO; unpublished data), whereas the reported Ki value 
of KTZ inhibition on morphine-3-glucuronide formation was 118 μM in the absence of BSA 
(Takeda et al., 2006). 
Recent studies in this laboratory have demonstrated that the magnitude of an in 
vivo inhibitory DDI with a UGT2B7 substrate as the object drug may be predicted accurately 
from a Ki value generated in vitro when incubations of HLM are conducted in the presence of 
BSA. Long-chain unsaturated fatty acids released from the microsomal membrane during the 
course of an incubation act as potent competitive inhibitors of UGT2B7 and UGT1A9 resulting in 
over-estimation of the Michaelis-Menten constant (Km) and Ki values of substrates and inhibitors 
of these enzymes (Rowland et al., 2007 and 2008a). BSA sequesters the inhibitory unsaturated 
long-chain fatty acids and, as a consequence, Ki (and Km) values are reduced by approximately an 
order of magnitude compared to data generated in the absence of albumin (Miners et al., 2006 and 
2010). Importantly, in vitro Ki values obtained in the presence of 2% BSA accurately predicted 
the magnitude of the FLZ – AZT and VPA – lamotrigine (LTG) interactions in vivo (Rowland et 
al., 2006; Uchaipichat et al., 2006a). 
The primary aim of the present study was to employ in vitro – in vivo 
extrapolation (IV-IVE) to identify potential DDIs resulting in inhibition of COD glucuronidation. 
In vitro inhibition data were generated using HLM, with and without BSA, as the enzyme source. 
Drugs investigated included those previously identified from in vitro and in vivo inhibition 
studies with UGT2B7 substrates (viz. FLZ, KTM, KTZ, and VPA). The work additionally sought 
to confirm the involvement of both UGT2B7 and UGT2B4 in C6G formation and characterize the 
effect of BSA (2%) on the kinetics of COD glucuronidation in vitro, and to assess the relative 
inhibition of these enzymes by inhibitors of human liver microsomal COD glucuronidation. 
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1.2 Review of the Literature 
1.2.1 Overview of drug metabolism  
Generally, a drug that is administered by any route other than intravenous (IV) 
route must be absorbed from the site of administration into the bloodstream. Following 
distribution into various body fluids and tissues, including those sites where the drug exerts its 
pharmacological effect(s), it is eliminated from the body, by metabolism and excretion (Holford 
and Sheiner, 1981; Holford, 2004). Metabolism is an important process that determines the 
metabolic clearance of an administered drug. For a drug that undergoes metabolism, several 
factors, such as certain disease states, genetics, and DDIs, may influence the extent of metabolism 
and lead to toxic or subtherapeutic plasma drug concentrations (Holford, 2004). Ideally, 
metabolic reactions generate more polar, inactive metabolites that are readily excreted from the 
body in urine or bile. However, in some cases, metabolites with potent biological activity or toxic 
properties are generated (Buxton, 2006).  
 The metabolic conversion of drugs is enzymatic in nature. The enzyme systems involved 
in the metabolism of drugs are mainly localized in the liver. Other organs with significant 
metabolic capacity include the gastrointestinal (GI) tract, kidneys, and lungs. Within a given cell, 
most drug metabolizing activity is found in the endoplasmic reticulum (ER) and the cytosol, 
although drug metabolism also can occur in the mitocondria, nuclear envelope, and plasma 
membrane. Upon homogenization and differential centrifugation of tissues, the ER breaks up and 
fragments of the membrane form microvesicles, referred to as microsomes. Drug-metabolizing 
enzymes can be classified into two major groups, functionalisation and conjugation (Gonzalez 
and Tukey, 2006).  
1.2.1.1 Functionalisation 
Functionalisation enzymes are responsible for the either the introduction of a 
polar functional group or the unmasking of a polar functionality. The three main types of 
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functionalisation reactions are oxidation, reduction and hydrolysis. Oxidation reactions are 
catalyzed by enzymes, such as CYP, flavin monooxygenase (FMO) and amine, xanthine, alcohol 
and aldehyde oxidases (Zhang et al., 2006). Of these, the CYP enzymes are considered the main 
functionalisation enzyme. It is estimated that CYP superfamily enzymes are involved in the 
metabolism, accounting for ∼75% of marketed drugs (Guengerich, 2008). CYP catalyzes many 
reactions which mostly involve oxidation such as N-, O-, and S-dealkylation, N-oxidation, and C- 
and N-hydroxylation etc. (Gonzalez and Tukey, 2006). The other possible functionalisation 
reactions are epoxidation, oxidative deamination, nitroreduction, azoreduction, reductive 
dehalogenation and hydrolysis reactions. Thus, functionalisation reactions a functional group (e.g. 
-OH, -COOH, -NH2 or -SH) is typically introduced or ‘unmasked’. These reactions are not 
uncommonly followed by a conjugation reaction (Zhang et al., 2006). 
1.2.1.2 Conjugation reactions 
Conjugation enzymes lead to the formation of a covalent bond between a 
suitable functional group present in the parent compound or functionalisation metabolite with 
endogenously derived glucuronic acid, sulfate, glutathione, amino acid, or acetyl group. These 
generally polar conjugates are normally inactive and are excreted in the urine and feces. The 
major conjugation enzymes are UGT, glutathione S-transferase (GST), sulfotransferase (ST), N-
acetyltransferase (NAT), and methyltransferase (MT) (Gonzalez and Tukey, 2006). Table 1.1 
summarizes the characteristics of conjugation reactions. 
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Table 1.1. Characterization of conjugation reactionsa (Modified from Liston et al., 2001). 
aUGT, UDP-glucuronosyltransferase; UDPGA, Uridine diphosphate glucuronic acid; ST, Sulfotransferase: PAPS, 
3-phosphoadenosine-5-phosphosulfate; GST, Glutathione-S-transferase; NAT, N-acetyltransferase; RBCs, red 
blood cells; MT, Methyltransferase; SAM, S-adenosyl-L-methionin; CNS, Central nervous system. 
 
 
Conjugation 
enzyme 
Co-Factor Locations Reaction Common substrates 
UGT UDPGA Liver, kidney, 
intestine, lung, 
skin, prostate, 
brain 
Glucuronidation Acetaminophen  
Bilirubin  
Ethinylestradiol 
Morphine      
Lorazepam     
Oxazepam          
Valproic acid 
Lamotrigine   
Olanzapine 
ST PAPS Liver, kidney, 
intestine 
Sulfate conjugation Acetaminophen 
Albuterol 
Terbutaline 
Methyldopa 
GST Glutathione Liver, kidney Glutathione conjugation Azathioprine 
6-Mercaptopurine 
Nitroglycerin 
Organophosphates 
NAT Acetyl 
coenzyme A 
Liver, lung, 
spleen, gastric 
mucosa, RBCs, 
lymphocytes 
N-acetylation Dapsone 
Hydralazine 
Isoniazid 
Phenelzine 
Procainamide 
MT SAM Liver, kidney, 
lung, CNS 
Methylation Dobutamine 
Dopamine 
Levodopa 
Norepinephrime 
Serotonin 
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The most important conjugation reaction is glucuronidation, which is catalyzed by UGTs. This 
enzyme is responsible for the majority of all drugs metabolized by conjugation pathways. 
1.2.2 Glycosyltransferases (GTs) 
 Based on amino acid sequence and predicted structure, human UGT enzymes belong to 
the GT superfamily. GTs are a large family of enzymes that are involved in the biosynthesis of 
oligosaccharides, polysaccharides, and glycoconjugates. They catalyze the transfer of a sugar 
moiety from an activated donor sugar onto a protein, lipid, deoxyribonucleic acid (DNA) or small 
molecule (Breton et al., 2006). The classification of GTs is based on the identities of their amino 
acid sequences. GTs have been classified into 91 gene families, available from the continuously 
updated carbohydrateactive enzyme database (CAZy) at http://afmb.cnrs-mrs.fr/CAZY (Campbell 
et al., 1998; Coutinho et al., 2003). Currently, structural information is available for only a 
limited number of GT families, revealing two distinct structural folds, GT-A and GT-B (Breton et 
al., 2006). GT folds have been observed to consist primarily of α/β/α sandwiches, similar or very 
close to the Rossmann-like fold, a classical structural motif (six-stranded parallel β-sheet with 
321456 topology) found in many nucleotide binding proteins (Lesk, 1995). The GT-A fold 
consists of a single α/β/α sandwich (a seven stranded β-sheet with 3214657 topology in which 
strand 6 is antiparallel to the rest) that resembles a Rossman-like fold (Fig.1.1A). The central β-
sheet is flanked by a smaller one, and the association of both creates the active site. Almost all the 
GT-A family members have a common DxD motif, which is involved in coordinating a divalent 
cation, usually Mn2+, in the catalytic centre. This metal ion is required for the binding of the 
nucleotide sugar (Wiggins and Munro, 1998; Breton and Imberty, 1999; Breton et al., 2006). 
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The GT-B fold (Fig.1.1B) consists of two separate Rossmann domains with a 
connecting linker region and a catalytic site located between the domains. Carboxy (C)-terminal 
domain corresponds to the nucleotide-binding domain, while amino (N)-terminal domain binds 
the acceptor. Variations are more pronounced in the N-terminal domains, in the loops and helices 
which point towards the active site (Breton et al., 2006). 
 
 
Figure 1.1 Ribbon diagram of GTs (Taken from Breton et al., 2006):  
A) GT-A fold; mouse α-1,4-N-acetylhexosaminyltransferase complexed with UDP-GalNAc. 
              B)   GT-B fold; E. coli MurG complexed with UDP-GlcNAc. 
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1.2.3 UDP-glucuronosyltransferases (UGTs)   
1.2.3.1 The glucuronidation reaction 
Glucuronidation is a synthetic reaction catalyzed the UGT enzymes (EC 
2.4.1.17) (Miners and Mackenzie, 1991; Radominska-Pandya et al., 1999; Tukey and Strassburg, 
2000). This reaction involves the covalent linkage (or “conjugation”) of a suitable functional 
group present on a substrate with glucuronic acid (Fig.1.2). In mammals, glucuronic acid is the 
main sugar that is used to prevent the accumulation of waste products of metabolism and 
lipophilic chemicals from the environment to toxic levels in the body. In the glucuronidation 
reaction, glucuronic acid from the donor uridine diphosphate glucuronic acid (UDPGA) is 
covalently linked to a functional group, most commonly -OH, -COOH, -NH2 or -SH group on the 
target molecule (aglycone), leading to the formation of O-, N-, or S-glucuronides, respectively 
(Radominska-Pandya et al., 1999; King et al., 2000; Gonzalez and Tukey, 2006).  
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Figure 1.2  Scheme for the conjugation of substrates with glucuronic acid.  
(Modified from Gonzalez and Tukey, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
OH
OH
O
OH
OHO
R
O H
P
O
P
O
OH OH
O O
O
OHOH
N
NH
O
O
Uridine diphosphoglucuronic acid 
(UDPGA) 
O
OH
OH
OOH
OHO
R
OH
P
O
P
O
O O
OH OH
O
N
OH OH
NH
O
O
+
O-glucuronide + Uridine diphosphate (UDP) 
(Ether glucuronidation) 
O
OH
OH
OOH
OHO
C
R
O + UDP
O-glucuronide (Ester glucuronidation) 
O
OH N
OH
OH
OHO
R
+    UDP
N-glucuronide 
O
OH S
OH
OH
OHO
R
+     UDP
S-glucuronide 
O
OH
OH
OH
N
N
H2C
O
O
OHO
H2C
S
O
+    UDP
Sulfinpyrazone C-glucuronide 
C
R OH
O
Carboxyl group 
R
NH2
Amino group 
Thiol group 
R
SH
NN
CH2H
O O
CH2 S
O
Sulfinpyrazone group 
Hydroxyl group 
  
11 
11
Glucuronidation additionally serves as an elimination pathway in humans for 
numerous dietary chemicals, environmental pollutants, and endogenous compounds (e.g., 
bilirubin, bile acids, and hydroxysteroids). Moreover, glucuronidation facilitates excretion of 
these compounds and the products of functionalisation metabolism in urine and bile as their 
hydrophilic conjugates, and generally results in detoxification, although a limited number of 
glucuronides possess biological activity (Ritter, 2000).  
1.2.3.2 UGT heterogeneity 
A nomenclature system for the UGT superfamily based on divergent evolution 
of the genes is in place. Several novel UGT genes have been identified in the human, mouse and 
rat genomes and in other mammalian species. The mammalian UGT gene superfamily is 
classified on the basis of sequence homology. It currently has 117 members that can be divided 
into four families, UGT1, UGT2, UGT3 and UGT8 (Fig.1.3) (Burchell et al., 1991; Mackenzie et 
al., 1997; Mackenzie et al., 2005). The UGT1 and UGT2 families are most efficient at using 
UDPGA as the glycosyl donor. However, other uridine diphosphate (UDP) sugars, including 
UDP glucose and UDP xylose, may be used as the sugar donor by these enzymes (Senafi et al., 
1994; Mackenzie et al., 2003).  
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Figure 1.3 A Phylogram of the human UGT families. 
(Modified from Mackenzie et al., 2005). 
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The human UGT1 family constitutes a complex gene on chromosome 2q37 
(Fig.1.4A). It comprises 13 individual promoters/first exons that encode the unique N-terminal 
domains of the UGT1A proteins and a shared set of exons 2–5 that encode the C-terminal 
domain, which is identical in all UGT1A family members (Owens and Ritter, 1992; Mackenzie et 
al., 2005). Each first exon directs the synthesis of RNA transcript which is then spliced to the 
shared exons 2–5. The human UGT1 gene extends over approximately 200 kb. Nine members 
(UGT1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, and 1A10) can be generated from the UGT1. 
However, four members (UGT1A2P, 1A11P, 1A12P and 1A13P) contain mutations and are 
designated as pseudogenes (Tukey and Strassburg, 2000; Mackenzie et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Oganization of the human UGTs (Modified from Mackenzie et al., 2005): 
A) UGT1 family; Each exon 1 is represented by a coloured rectangle, labeled A1, A2, A3, etc. 
and its position relative to exons 2–5 is indicated. Exons 2–5, which are joined to each first exon 
in the mature transcript, are shown in grey.    
B) UGT2 family; Each gene in the human consisting of six exons, is represented by a coloured 
rectangle, except for that which is labeled ‘2A1/2’, which represents seven exons. The human 
UGT2A1 and UGT2A2 genes contain unique first exons (2A1 and 2A2) and a shared set of five 
downstream exons (exons 2–6 in grey). Pseudogene names end in the label P. 
A 
Chromosome 2q37
B 
Chromosome 4q13
2A1 2A2 
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The human UGT2 family consists of the UGT2A and UGT2B subfamilies; 
human UGT2 genes extend over approximately 1.45 Mb. The UGT2A subfamily contains three 
members (UGT2A1, 2A2, and 2A3), whereas the UGT2B includes seven members (UGT2B4, 
2B7, 2B10, 2B11, 2B15, 2B17, and 2B18) and five pseudogenes (UGT2B24P, 2B25P, 2B26P, 
2B27P, and 2B29P) (Mackenzie et al., 2005). In contrast to the UGT1 family, the UGT2 family is 
encoded by separate genes clustered on chromosome 4q13 (Fig.1.4B). Each UGT2 gene 
comprises six exons that are not shared between the UGT2 family members, excepting UGT2A1 
and 2A2 which are encoded by seven exons (Tukey and Strassburg, 2000; Mackenzie et al., 
2005). By contrast, the UGT2A3 gene is composed of six exons that are not shared with UGT2A1 
and 2A2 (Mackenzie et al., 2005). 
The recently identified human UGT3 family comprises only two members, 
UGT3A1 and 3A2. They apparently consist of seven exons and are located on chromosome 
5p13.2 (Mackenzie et al., 2005). The human UGT8 family consists of a single gene (UGT8A1) 
that encodes UDP-galactose ceramide galactosyltransferase. The gene consists of five protein-
coding exons on human chromosome 4q26 (Mackenzie et al., 2005).  
1.2.3.3 UGT membrane localization 
The UGTs are membrane-bound glycoproteins consisting of approximately 530 
amino acids in length localized in the ER and nuclear compartment of cells (Radominska-Pandya 
et al., 1999) (Fig.1.5). The majority of the protein is in the ER lumen and is composed of two 
functional domains, the N-terminal and C-terminal domains. The first 25 or so residues of the N-
terminal domain form a signal sequence that directs the enzyme to the ER and is later cleaved. 
Thus the length of the mature protein is between 500 and 510 residues (Kurkela et al., 2003). The 
enzymes are 50-60 kDa in size and most of their mass is located in the ER lumen with the 
carboxyl-terminal 19–26 amino acids protruding into the cytoplasm with a single-pass 17-residue 
long transmembrane helix near the C-terminal domain (Meech and Mackenzie, 1998; 
Radominska-Pandya et al., 1999). The presence of the transmembrane domain is a critical 
requirement for UGT activity, whereas the cytoplasmic domain seems to be a non-essential 
modulator of activity (Meech et al., 1996). The N-terminal domain is primarily responsible for 
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binding aglycones, whereas the C-terminal domain binds the common co-substrate, UDPGA 
(Mackenzie, 1990).  
Mammalian UGTs may function as dimers or higher oligomers (Meech and 
Mackenzie, 1997; Finel and Kurkela, 2008). Evidence for a functional dimerization between 
UGTs is provided by studies on mutated forms of UGT2B1. Catalytically active homodimers of 
the rat enzyme UGT2B1 that appear to interact through their amino terminal regions have been 
detected (Meech and Mackenzie, 1997). Homodimers of rat UGT1A6 (Ikushiro et al., 1997), 
human UGT1A1 (Ghosh et al., 2001), and human UGT1A9 (Kurkela et al., 2003), and 
heterodimers of UGT2B1 and UGT1A6 (Ikushiro et al., 1997) have also been detected by 
chemical cross-linking and co-immunopurification. It has been postulated that the stability of the 
interaction or the rates of dimerization may be governed by the specific UGT monomers involved 
and/or by interaction with substrate (Radominska-Pandya et al., 1999). 
 
 
 
 
 
 
 
 
 
Figure 1.5 Schematic representation of human UGT topology. 
(Modified from Radominska-Pandya et al., 1999 and Finel and Kurkela, 2008). 
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1.2.3.4 UGT isoenzyme selective substrates 
UGTs have highly similar C-terminal domains and highly variable N-terminal 
domains, thereby imparting to each enzyme a distinct, but often overlapping set of substrate 
specificities (Meech and Mackenzie, 1998; Miners et al., 2004 and 2006). Many studies have 
been carried out using chimeric constructs of different UGT cDNAs followed by expression of 
the hybrid protein. These data indicate that the N-terminal domain may be important in substrate 
selectivity of the different UGTs (Mackenzie, 1990; Mackenzie et al., 2005). Mackenzie (1990) 
showed that exchanging the N-terminal half between two rat UGT2B forms, UGT2B2 and 
UGT2B3, resulted in switching of their respective substrate selectivities. In addition, site-directed 
mutagenesis studies have provided important insights into UGT structure-function relationships, 
particularly the importance of an N-terminal domain histidine. Mutation of the conserved N-
terminal domain histidine to a proline in UGT 1A1, 1A6 and 1A9 (viz. UGT1A1(His39Pro), 
UGT1A6(His38Pro) and UGT1A9(His37Pro)) resulted in proteins that lacked the ability to 
metabolize 4-methylumbelliferone (4-MU), 1-naphthol (1-NP) and naproxen, while all 
glucuronidated LTG. Conversely, the UGT2B7(His35Pro) mutation resulted in a protein that 
lacked activity towards all substrates. Substitution of leucine-40 for histidine in UGT2B10 
provided an enzyme that glucuronidated 4-MU and 1-NP (Kerdpin et al., 2009). The 
UGT1A3(His40Pro) mutation conferred LTG and trifluoperazine (TFP) glucuronidation, whereas 
the UGT1A4(Thr36Ile) conferred 1-NP and 4-MU glucuronidation (Kubota et al., 2007). In 
contrast to the N-terminal domain, substrate selectivity is not associated with the C-terminal 
domain (Mackenzie, 1990; Ritter et al., 1992; Meech et al., 1996). For examples, exchanging the 
C-terminal 232 residues of the rat proteins UGT2B2 and UGT2B3 did not the affect substrate 
selectivity of either enzyme (Mackenzie, 1990), while substituting the C-terminal 231 amino 
acids of the rabbit enzymes UGT2B16 and UGT2B13 did not alter UGT2B16 substrate selectivity 
(Li et al., 1997).  
Furthermore, considerable effort has been directed toward predicting the 
substrate and inhibitor selectivities of human UGTs. Molecular modeling techniques including 
pharmacophore, 2D, and 3D quantitative structure-activity relationships (QSAR) have been 
developed (Sorich et al., 2002; Smith et al., 2003a and 2003b; Sorich et al., 2008). 
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Pharmacophores represent a configuration of structural features associated with biological activity 
(in this case metabolism by an individual UGT form), and represent one of the most intuitive 3D-
descriptors (Miners et al., 2004; Smith et al., 2004). Common features pharmacophores for 
UGT1A1, UGT1A4, and UGT1A9 include an essential glucuronidation feature and two 
hydrophobic domains, with the possible contribution of a hydrogen bond acceptor in the case of 
UGT1A9 (Sorich et al., 2002; Smith et al., 2003a and 2003b;  Miners et al., 2004; Smith et al., 
2004). This observation implies the ability of most UGTs to confer glucuronidation activity 
towards small hydrophobic compounds such as simple phenols (Smith et al., 2004), although 
increasing structural complexity results in greater enzyme selectivity due to steric, polar and 
hydrophobic interactions (Miners et al., 2010).  
To date, only limited numbers of enzyme-selective UGT substrates and 
inhibitors have been identified (Table 1.2) (Miners et al., 2006 and 2010). Just two selective 
inhibitors have been characterized; hecogenin and FLZ, which inhibit UGT1A4 and UGT2B7, 
respectively (Uchaipichat et al., 2006a and 2006b). Although apparently form selective substrates 
have been used as inhibitors in some studies, further confirmation of inhibition selectivity is 
advisable given previous experience with other enzyme systems (e.g. potent inhibition of 
CYP2D6 by the CYP3A4 substrate quinidine) (Miners et al., 2006). Indeed, there is an evidence 
that bilirubin, a specific UGT1A1 substrate, may inhibit UGT1A4 (Ghosal et al., 2004).  
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a Probably partially selective, with a contribution from UGT1A3.     
b Supporting experimental data not provided.       
 
 
 
Enzyme Substrates References 
UGT1A1 Bilirubin; β-estradiol a; Etoposide (Bosma et al., 1994; Watanabe et al., 2003; Lepine et al., 2004; Itaaho et al., 2008) 
UGT1A3 Hexafluoro-1α, 25-dihydroxyvitamin D3; R-lorazepam (Court, 2005; Kasai et al., 2005) 
UGT1A4 1’-Hydroxymidazolam; Trifluoperazine (Di Marco et al., 2005; Uchaipichat et al., 2006a; Zhu et al., 2008) 
UGT1A6 Deferiprone; Serotonin (Krishnaswamy et al., 2003; Benoit-Biancamano et al., 2009) 
UGT1A9 Mycophenolic acid; Phenylbutazone; Propofol; 
Sulfinpyrazone 
(Bernard and Guillemette, 2004; Soars et al., 2004; Court, 2005; Picard et al., 2005; 
Kerdpin et al., 2006; Nishiyama et al., 2006) 
UGT2B7 Denopamine; Epirubicin; 6α-Hydroxyprogesterone; 
21-Hydroxyprogesterone; Morphine (3- and 6- 
glucuronidation); Zidovudine 
(Barbier et al., 2000; Innocenti et al., 2001; Court et al., 2003; Stone et al., 2003; 
Court, 2005; Kaji and Kume, 2005; Bowalgaha et al., 2007; Ohno et al., 2008) 
UGT2B15 S-oxazepam; S-lorazepamb (Court et al., 2002; Court, 2005) 
Table 1.2 Selective substrates of the major hepatically expressed human drug-metabolizing UGT enzymes (Taken from Miners et al., 2010). 
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1.2.4 UDP-glucuronosyltransferase 2B7 (UGT2B7)  
As noted above, UGT genes have been classified into UGT1A and UGT2B 
subfamilies. Among the UGT2B subfamily, UGT2B7 is the most important member since it 
conjugates a large variety of compounds (Coffman et al., 1998; Radominska-Pandya et al., 2001; 
Miners et al., 2010). It is predominantly expressed in the liver, but tissue distribution analysis has 
also demonstrated expression in the GI tract, kidney, pancreas and brain (Radominska-Pandya et 
al., 2001). Typical substrates of UGT2B7 are endogenous substances such as hydroxy metabolites 
of steroid hormones and bile acids (Jin et al., 1993) and xenobiotics including drugs like 
morphine, COD, and other opioid derivatives (Coffman et al., 1998; Court et al., 2003), and 
carboxylic acid containing compounds that include nonsteroidal anti-inflammatory drugs 
(NSAIDs; ketoprofen, ibuprofen, diclofenac, and naprofen), the lipid reducer gemfibrozil or the 
antiepileptic VPA (Sakaguchi et al., 2004), and a wide range of hydroxylated benzo(a)pyrene and 
2-acetylaminofluorene derivatives (Jin et al., 1993).  
1.2.4.1 Structure of the UGT2B7 gene 
Human UGTs belong to the GT1 family and are predicted to adopt a GT-B fold 
(Campbell et al., 1997; Coutinho et al., 2003; Breton et al., 2006). There has been a significant 
effort to characterize the crystal structures of UGT enzymes in recent years. N-and C-terminal 
domain for UGT2B7 were identified using an E. coli expression strategy. The C-terminal domain 
of UGT2B7 (UGT2B7CT, residues 285-451) was well behaved and crystallized readily. The 1.8 
Å resolution x-ray crystal structure of the UGT2B7CT was elucidated. The asymmetric unit 
contains two 2B7CT molecules that pack together to form an asymmetric dimer (Fig.1.6A). The 
2B7CT structure is a globular domain with a Rossman-type fold (Fig.1.6B). At the core of the 
protein is a single parallel β-sheet consisting of six individual strands surrounded by seven α-
helices (Miley et al., 2007). 
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The UGT2B7 gene is composed of six exons spanning approximately 16 kb. The 
lengths of exons 1 to 6 are 721, 149, 132, 88, 220 and 531 bp, respectively, with introns ranging 
from 0.7 to 4.2 kb (Fig.1.7) (Carrier et al., 2000). One major difference observed between 
UGT2B7 and the other UGT2B genes is the size of the introns, which are smaller than the 
corresponding portions of the other genes (Carrier et al., 2000).  
 
 
 
 
 
 
 
 
 
 
 
BA 
Figure 1.6 Overall structure of the UGT2B7CT (Taken from Miley et al., 2007): 
A) Asymmetric dimer present in the crystallographic asymmetric unit.  
B) Ribbon cartoon of UGT2B7CT with labeled secondary structure elements. 
Figure 1.7 Structure of the human UGT2B7 gene. 
 (Modified from Carrier et al., 2000). 
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1.2.4.2 UDPGA binding site  
A hallmark feature of GT-B fold-containing enzymes is the di-phosphate 
nucleotide sugar binding site formed by the C-terminal domain. Structurally characterized GT-B 
superfamily enzyme nucleotide-sugar binding sites utilize a common structural scaffold. 
However, the natures of the specific interactions with the donor ligands vary, even amongst 
enzymes in the same GT family (Miley et al., 2007). The first suggestion that the UDPGA 
binding site is in the C-terminal domain was based on studies with chimeric UGTs (Mackenzie, 
1990). Later, results from inhibitors directed at specific amino acids, photoaffinity labeling, and 
analysis of amino acid alignments confirmed that the UDPGA binding site is between residues 
350 and 400; however, UDPGA interacts not only with the C-terminal but also with the N-
terminal domains of UGT (Radominska-Pandya et al., 1999). Comparison of UGT2B7CT with 
other GT1 family enzyme structures from bacteria and plants (GtfA and VvGT1) suggests that 
human UGT2B7 binds UDPGA with an analogous site (Fig.1.8). The UDPGA binding site in 
UGT seems to be remarkably similar to the UDP-glucose binding site in other GT1 enzymes 
(Mulichak et al., 2001; Li et al., 2007; Miley et al., 2007). Although the majority of secondary 
structure elements are similar, all structures significantly differ in both length and secondary 
structure for the amino acids connecting Cβ2 and Cβ3. In VvGT1, both a 3/10 helix and α-helix 
Cα2 are present in this region, while in both 2B7CT and GtfA a shorter loop structure is observed 
(Miley et al., 2007).  
Furthermore, the UDPGA binding site has been studied by chemical 
modification (Ouzzine et al., 2000) and site-directed mutagenesis (Miley et al., 2007) to elucidate 
the specific residues making contacts with UDPGA. The site-directed mutagenesis implicates 
several residues interacting with the: 1) uracil base, 2) phosphate, or 3) glucuronic acid of the 
predicted UDPGA binding region. 
 
 
 
 
  
22 
22
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Mutations at residues predicted to interact with the di-phosphate and glucuronic 
acid moiety have suggested significant effects on UGT2B7 function. Mutation at His374 virtually 
eliminates activity. It has been revealed that His374 assists in neutralizing the negative charge on 
the β-phosphate where the di-phosphate moiety is predicted to bind (Li et al., 2007; Miley et al., 
2007). Mutation at several residues interacting with the di-phosphate moiety suggests that Asn378 
is predicted to hydrogen bond to α-phosphate; Gly379 is involved with a pocket formed 
underneath the α-phosphate; and Thr373 is predicted to interact with the α-phosphate via a water-
or ion-mediated contact (Miley et al., 2007). Several residues are predicted to hydrogen bond to 
the glucuronic acid moiety. Asp398 and Gln399 are predicted to interact with O3'/O4' and 
O2'/O3' atoms of glucuronic acid, respectively. Mutation of Asp398 is suggested that a negative 
charge, not just hydrogen bonding potential, is important at this position. In addition, mutation at 
Asn378 is predicted to involve with donor sugar selectivity (Miley et al., 2007). 
 
Figure 1.8 Partial sequence alignments of GT1 family enzymes.  
(Modified from Miley et al., 2007). 
3/10 
Cα2 
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1.2.4.3 Aglycone binding site 
 As mentioned above, the C-terminal domain binds UDPGA, whereas the N-terminal 
domain, which is formed from first 260 amino acids of the mature protein, binds the aglycone 
(Mackenzie, 1990). An N-terminal membrane-region located between residues 140-240 may be 
needed to help highly lipophilic substances to reach the active site of the enzyme (Radominska-
Pandya et al., 2005). Maltose binding protein (MRP) fusion constructs with the N-terminal 
domain of UGT2B7 were analyzed by nuclear magnetic resonance (NMR) spectroscopy and used 
to identify the opioid binding site of UGT2B7 (Coffman et al., 2001 and 2003). The results 
demonstrated that the binding site of morphine in UGT2B7 is within amino acids 84 to 118 of the 
N-terminal domain (Coffman et al., 2003). Furthermore, a recent paper provides evidence for 
multiple substrate binding and effector sites of UGT2B7 (Uchaipichat et al., 2008). Multisite 
modeling of kinetic and inhibition data is consistent with the existence of two “catalytic” sites for 
AZT, 4-MU, and 1-NP within the UGT2B7 substrate binding domain. The complex interaction 
observed between UGT2B7 substrates, which includes activation and inhibition (due either to 
competitive displacement or changes in the substrate dissociation constant (Ks) or the maximum 
velocity (Vmax) via an effector site), indicates that careful experimental design and kinetic 
interpretation are necessary for DDIs studies involving this enzyme (Uchaipichat et al., 2008). 
1.2.4.4 Catalytic mechanism of UGT2B7 
A homology model of UGT2B7 showed that UGT2B7 has residues analogous to 
VvGT1 at key catalytic positions (Miley et al., 2007). Human UGT2B7 use a serine hydrolase-
like catalytic mechanism where His35 and Asp151 function as a catalytic diad. His35 is involved 
in deprotonation of the phenolic group of the acceptor ligand, facilitating nucleophilic attack at 
the C1 atom of glucuronic acid (Fig.1.9).   
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Figure 1.9 Proposed catalytic reaction mechanism for human UGT2B7.  
(Modified from Miley et al., 2007). 
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Protonated His35 is stabilized by a neighboring aspartic acid at position 151. 
The His35 residue predicted in the active site of UGT2B7 is invariant in both human and plant 
enzymes, while the stabilizing aspartic acid is invariant in humans and the vast majority of plant 
enzymes (Miley et al., 2007). 
1.2.5 Analysis of enzyme kinetics 
Enzyme kinetics is the study of the chemical reactions that are catalyzed by 
enzymes. In enzyme kinetics, the reaction rate is measured and the effects of varying assay 
conditions on the reaction investigated. Enzyme kinetic studies may also reveal insights into the 
catalytic mechanism of enzyme, its role in metabolism, how its activity is controlled, and how a 
drug or other compound might inhibit the enzyme. It usually starts with the investigation of the 
behavior of the enzyme substrate and its conversion into product. The next steps are the 
examination of the role of cofactors, inhibitors or activators (Bisswanger, 2008).  
1.2.5.1 Graphical determination of the Km and Vmax parameters 
 Because the enzyme velocity versus substrate concentration curve (Fig.1.10A) is a 
hyperbolic (non-linear plot), it is extremely difficult to determine Vmax and Km. Several 
disadvantages mentioned previously for non-linear plots can be eliminated by applying 
linearization methods (Marangoni, 2003). The kinetic constants can be derived easily from axis 
intercepts or from the slopes of the straight lines. In addition, an important advantage of 
linearization methods is the analysis of enzyme kinetic methods when two or more ligands are 
varied, as in enzyme inhibitions or multiple substrate reactions. The respective mechanisms can 
be identified from the resulting straight line pattern. There are many simple linear transformations 
of the Michaelis-Menten equation such as Lineweaver-Burk plot, Hanes-Woolf plot, Eadie-
Hofstee plot etc. (Fig.1.10) (Segel, 1993; Marangoni, 2003). 
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Figure 1.10 Representative different plots of the Michaelis-Menten kinetic (Modified from 
Segel, 1993 and Bisswanger, 2008): 
A) Direct plot (enzyme velocity versus substrate concentration).  
B) Lineweaver-Burk plot.  
C) Hanes-Woolf plot. 
D) Eadie-Hofstee plot. 
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1.2.5.2 Typical enzyme kinetics and Michaelis-Menten approach 
The general rate equation for reaction based on a single site substrate-enzyme 
interaction was proposed by Henri in 1903. Henri’s equation accounted for the observation that 
the initial rate of a reaction was directly proportional to the concentration of enzyme preparation, 
but increased in a nonlinear manner with increasing substrate concentration up to a limiting 
maximum rate.  Ten year later Michaelis and Menten confirmed Henri’s equation and presented a 
slightly modified version of the rate equation. The derivation of this approach was based on the 
following assumptions (Segel, 1993):   
a) The enzyme (E) is a catalyst.  
b) The E and substrate (S) react rapidly to form an enzyme-substrate (ES) complex. 
c) Only a single S and a single ES complex are involved and the ES complex breaks 
down directly to form free E and product (P). 
d) E, S, and the ES complex are at equilibrium; that is, the rate at which ES dissociation 
to E + S is much faster than the rate at which ES breaks down to form E + P. 
e) The substrate concentration [S] is very much larger than the enzyme concentration 
[E] so that the formation of an ES complex does not alter the [S]. 
f) The overall rate of the reaction is limited by the breakdown of the ES complex to 
form free E and P. 
g) The velocity (υ) is measured during the very early stages of the reaction so that the 
reverse reaction is insignificant.  
These assumptions are called the quasi-equilibrium or rapid equilibrium 
assumption. The overall reaction may be described as: 
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where, E, S, ES and P represent enzyme, substrate, enzyme-substrate complex 
and product, respectively. This reaction is described by the Michaelis-Menten equation:  
 
where, υ is the metabolic rate or velocity, [S] is the substrate concentration, Vmax 
is the maximum velocity, and Km (k-1/k1) is the Michaelis-Menten constant (concentration giving 
0.5Vmax) (Segel, 1993). 
1.2.5.3 ‘Atypical’ enzyme kinetics 
Assumptions of the Michaelis-Menten equation implicit are the substrate-
enzyme interaction occurs at only one site per enzyme and that each site operates independently 
from others. However, many drug metabolism reactions catalyzed by CYP and UGT exhibit non 
hyperbolic or ‘atypical’ kinetic behavior (Houston and Kenworthy, 2000; Uchaipichat et al., 2004 
and 2006b). In cooperative kinetics, binding of one substrate molecule induces structural and/or 
electronic changes that result in altered substrate binding affinities in the remaining vacant sites. 
The substrate binding affinities can theoretically be either increased (positive cooperativity) or 
decreased (negative cooperativity). Binding of substrate and nonsubstrate ligands which can act 
as activators or inhibitors at a site other than the active site can affect on enzyme activity. These 
responses can be homotropic or heterotropic. Homotropic responses refer to the allosteric 
modulation of enzyme activity strictly by substrate molecules and heterotropic responses refer to 
the allosteric modulation of enzyme activity by nonsubstrate molecules or combinations of 
substrate and nonsubstrate molecules (Marangoni, 2003). 
There are three approaches, ‘naïve’, empirical, and mechanistic, which are 
generally applied to the analysis of atypical kinetics in vitro. The first approach utilizes the 
Michaelis–Menten equation regardless of the kinetic behavior observed, ignoring any evidence of 
sigmoidicity or convexity in the rate-substrate concentration profile. Use of empirical models 
represents a useful tool for the preliminary analysis of data. However, this approach provides no 
E  +  S ES E  +  S + P k1 k-1 
kP 
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mechanistic information of the interactions between homotropic or heterotropic ligands. 
Mechanistic approaches use multisite kinetic models that allow the simultaneous fit of multiple 
sets of data to a single equation (Houston and Kenworthy, 2000; Houston and Galetin, 2005). 
A-1) Empirical modeling approaches for homotropic cooperative 
Homotropic effects represent alterations in either binding affinity or rate of 
product formation after the binding of a second molecule of the same substrate to the enzyme 
active site. Enzyme activity may be either increased in a substrate concentration-dependent 
manner (sigmoidal kinetic profiles defined as autoactivation) or decreased (convex kinetic 
profiles defined as substrate inhibition and apparent biphatic kinetics) (Ueng et al., 1997; Shou et 
al., 1999; Lin et al., 2001; Galetin et al., 2002). 
a) Autoactivation or sigmoidal kinetics 
Autoactivation (positive homotropic cooperativity) results in increased binding 
affinity for a second substrate molecule. The rate versus substrate concentration plot is sigmoidal 
while the Eadie-Hofstee plot shows a boomerang shape (Fig.1.11B). The sigmoidal rate plot can 
be described by the Hill equation (equation 1.2) (Houston and Kenworthy, 2000): 
  
where substrate concentration resulting in 50% of Vmax (S50) is analogous to the 
Km parameter, and n is the Hill coefficient reflecting the degree of sigmoidicity. In terms of 
clearance, the sigmoidal rate plot translates to a gradual increase in the clearance as substrate 
concentration is increased to reach a maximum followed by a decrease in the clearance due to 
saturation, as seen for the Michaelis-Menten case (Houston and Kenworthy, 2000). Equation 1.3 
describes the relationship between the various parameters in the Hill equation and the maximum 
clearance (CLmax): 
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Recently, sigmoidal or autoactivation kinetics have been observed in vitro for 
both CYP and UGT catalyzed reactions. For examples, the CYP3A4-catalyzed oxidation of 
testosterone (Ueng et al., 1997) and carbamazepine (Korzekwa et al., 1998), and CYP2C9-
mediated dapsone hydroxylation (Korzekwa et al., 1998) exhibit sigmoidal kinetics. Similarly, 
the formation of estradiol-3-glucuronide by UGT1A1 (Fisher et al., 2000), 4-
methylumbelliferone-β-D-glucuronide by UGT2B7 (Uchaipichat et al., 2004), 1-naphthol-β-D-
glucuronide by UGT1A9 (Uchaipichat et al., 2004) show autoactivation kinetics. The kinetic of 
VPA glucuronide formation is also characteristic of autoactivation kinetics, both in vivo in adult 
sheep and in vitro in sheep liver microsomes (Wong et al., 2007). 
b) Substrate inhibition 
A substrate that causes a decrease in the rate of product formation as its 
concentration increases will lead to a reaction that displays substrate inhibition kinetics (Lin et al., 
2001). With substrate inhibition, the Eadie-Hofstee plot is convex (Fig.1.11C). This reaction can 
be considered to be analogous to an uncompetitive type of inhibition mechanism. The initial 
clearance of substrate inhibition follows Michaelis-Menten kinetics; however, this parameter 
decreases more rapidly in the saturation portion of the curve due to the impact of the inhibition 
effect (Houston and Kenworthy, 2000). Substrate inhibition is described by the following 
equation 1.4:  
 
where Ksi is the constant describing the substrate inhibition interaction. Of the 
CYP-mediated reactions, substrate inhibition is commonly observed; for examples CYP2D6-
catalyzed O-demethylation of dextromethorphan, CYP3A4-catalyzed 6β-hydroxylation of 
testosterone, and CYP2C9-catalyzed methyl-hydroxylation of celecoxib (Lin et al., 2001). This 
kinetic behavior is also observed for substrates metabolized by UGT enzymes; for examples the 
formation of 4-methylumbelliferone-β-D-glucuronide by UGT1A9 (Tsoutsikos et al., 2004) and 
TFP glucuronidation by UGT1A4 (Uchaipichat et al., 2006a). 
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c) Apparent biphasic kinetics 
Negative cooperativity can alternatively lead to an apparent biphasic velocity 
versus substrate concentration curve that is frequently observed in two enzyme reactions. Here a 
high-affinity, low-capacity enzyme and a low-affinity, high-capacity enzyme contribute to a 
particular metabolic reaction (Houston and Kenworthy, 2000). The Eadie-Hofstee plot shows that 
the two components are clearly separated by a difference in their affinities for each enzyme 
(Fig.1.11D). This kinetics can be described by equation 1.5:  
 
There are many examples of biphasic kinetics for CYP enzymes. Naphthalene 
metabolism by CYP3A4 and naproxen metabolism by CYP2C9 demonstrated apparent biphasic 
kinetics suggestive of a low Km, low Vmax and Km, high Vmax components. Similar to CYP 
enzymes, morphine 3-glucuronide and morphine 6-glucuronide formation by UGT2B7 exhibited 
the apparent biphasic kinetic (Stone et al., 2003).  
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Figure 1.11 Representative kinetic profiles for Direct plot, Eadie-Hofstee plot, and clearance plot 
(Modified from Houston & Kenworthy, 2000). 
0
50
100
150
0 2 4 6 8 10
Substrate concentration
Ve
lo
ci
ty
0
50
100
150
0 10 20 30 40 50
Velocity / [Substrate]
Ve
lo
ci
ty
0
1
2
3
4
5
0.1 1 10
Substrate concentratiom
Cl
ea
ra
nc
e
A) Michaelis-Menten 
0
50
100
150
0 2 4 6 8 10
Substrate concentration
Ve
lo
ci
ty
0
50
100
150
0 10 20 30 40 50
Velocity / [Substrate]
Ve
lo
ci
ty
0
1
2
3
4
5
0.1 1 10
Substrate concentratiom
Cl
ea
ra
nc
e
B) Autoactivation 
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C) Substrate inhibition 
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D) Biphasic kinetic 
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A-2) Mechanistic approach for homotropic cooperativity 
Atypical kinetics in vitro can be analyzed by a mechanistic approach, the use of 
multisite kinetic models. This approach is based on the same rapid equilibrium/steady-state 
principles as the single-site Michaelis–Menten equation (Segel, 1993; Houston and Galetin, 
2005). The simplest model accommodating atypical kinetic properties when two molecules of the 
same substrate bind to the active site is presented in the Fig.1.12. Two binding sites, substrate-
enzyme (SE) and ES complex, are identical and no orientation differences in binding of S to E 
occurs (Segel, 1993; Houston and Kenworthy, 2000; Galetin et al., 2002). 
, 
 
 
 
 
 
 
This scheme is represented by following equation:  
 
 
 
In this scheme Ks represents the substrate dissociation constant and Kp is the 
effective catalytic rate constant. For enzymes with two binding sites, Vmax is equivalent to 
2Kp/[E]t, where [E]t is the total enzyme concentration. The Ks and Kp values change by the 
interaction factors α and β, respectively (Houston and Kenworthy, 2000). Autoactivation (positive 
cooperativity) may be a result of either increased binding affinity for a second substrate molecule 
(Ks changes by the factor α < 1), or changes in the Kp by the factor β in the two-substrate-bound 
complex (β > 1). In contrast, a negative cooperative effect is observed when the value of α is > 1, 
resulting in an apparent biphasic kinetics, or when the value of β is < 1, resulting in substrate 
Figure 1.12 A kinetic model for an enzyme with two-substrate binding sites, where the second 
substrate (S) molecule binds cooperatively (Taken from Geletin et al., 2002). 
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inhibition. However, combination of both positive and negative cooperativity may occur when 
both α and β change simultaneously. Furthermore, it should be mentioned that Michealis-Menten 
kinetics follow from this equation when α and β are equal to 1 (no interaction between the two 
substrate binding sites) (Houston and Kenworthy, 2000; Galetin et al., 2002, 2003; Atkins, 2005; 
Houston and Galetin, 2005). 
A-3) Heterotropic cooperativity 
In contrast to homotropic cooperativity, heterotropic effects involving two 
different substrates may result either in activation or inhibition of the rate of product formation 
(Ueng et al., 1997). In this case, the drug acting as substrate may yield classic hyperbolic 
behavior, but the second drug acting as modifier (activator or inhibitor) induces non-hyperbolic 
behavior (Korzekwa et al., 1998; Kenworthy et al., 2001; Galetin et al., 2002). Multisite kinetic 
equilibria models for both two-site and three-site models adopted from Segel (1993) are based on 
steady-state and rapid equilibrium approach allowing the simultaneous fit of multiple sets of data 
to a single equation (Segel, 1993; Galetin et al., 2002).  
a) Two-Site Model 
 A generic two-site model has been used to describe various effects on CYP3A4 
such as an activation of substrate metabolism and different types of inhibition, including mixed, 
partial, and competitive inhibition for substrates with hyperbolic or substrate inhibition kinetic 
properties (Kenworthy et al., 2001; Galetin et al., 2002, 2003; Houston and Galetin, 2005). 
Heterotropic cooperativity (either negative or positive effect) can be described by the generic 
two-site model (Fig.1.13A and equation 1.7). In the generic two-site model, the corresponding 
interaction factors associated with changes in binding affinity (Ks or Ki) are α-homotropic 
cooperativity, and δ-heterotropic cooperativity. The interaction factors associated with rate of 
product formation (Kp) are β (from SES, substrate-enzyme-substrate, complex) and γ (from MES, 
modifier-enzyme-substrate, complex), where M is modifiers, either activators (A) or inhibitors 
(I). This model can be applied to both activation (A, Ka) and inhibition (I, Ki) (Houston and 
Galetin, 2005). 
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a-1) Heterotropic inhibition or activation of a substrate with hyperbolic 
kinetics 
 
Equation 1.7 is applied to substrates showing hyperbolic type (Michaelis-
Menten) kinetics in the absence of modifiers. No interaction is observed between the substrate 
molecules (autoactivation); therefore, the kinetic model is simplified eliminating the interaction 
factor α. In addition, this model can be used to describe the partial inhibition when the formation 
of a complex containing two different substrate molecules is more or less favorable, depending on 
the δ value implying the changes in the binding affinities of the substrate and the modifier in the 
presence of each other. The interaction factor γ affecting alterations in product formation in the 
presence of a modifier molecule is defined by γ < 1 for inhibition and γ > 1 for activation (Table 
1.3) (Galetin et al., 2002). 
a-2) Heterotropic inhibition of a substrate with substrate inhibition kinetics  
A generic two-site model, with only one catalytically active site, has been 
applied to compounds showing substrate inhibition kinetic. It is assumed that the substrate 
inhibition site can not be occupied until the active site is filled (sequential binding of substrate 
molecules). The presence of a modifier molecule in the second binding site causes a decrease in 
product formation from SES complex, defined by the factor β (< 1) (equation 1.8). When γ is 
comparable to β (Table 1.3), the effect of a modifier is analogous to the binding of a second 
substrate molecule, and the substrate inhibition phenomenon remains. 
b) Three-Site Model 
A three-site model is more complex and describes kinetic behavior where both 
substrate and effector bind to two sites, and one site is unique to either molecule (Kenworthy et 
al., 2001). This model shows the existence of a distinct effector binding site, with the possibility 
of conformational changes upon the binding of the effector molecule (Ueng et al., 1997).  
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b-1) Heterotropic inhibition of a substrate showing sigmoidal kinetics 
The model presented in Fig.1.13B describes the inhibition of substrates showing 
sigmoidal kinetics. In the absence of the inhibitor, the substrate binds cooperatively with an 
interaction factor α (< 1); however, the interaction between two substrate binding sites resulting 
in an increase in the affinity of the vacant substrate sites is prevented in the presence of the 
inhibitor. An alteration in the Ki value by the interaction factor δ (< 1) is caused by the increased 
affinity of SE or ES and SES complexes (equation 1.9) (Kenworthy et al., 2001; Galetin et al., 
2002, 2003). 
b-2) Heterotropic activation of a substrate showing sigmoidal kinetics 
A three-site model for heterotropic activation is shown in Fig.1.13C and 
equation 1.10 describes the activation of a substrate showing sigmoidicity. The two substrate 
binding sites describe the cooperativity observed when the substrate is incubated alone and an 
activator molecule mimics the cooperative effects of the second substrate molecule and stimulates 
the metabolism of the substrate at a distinct activator site (Kenworthy et al., 2001). 
b-3) Partial inhibition of a substrate showing sigmoidal kinetics 
Similar to previous three-site model, cooperativity in substrate binding is 
maintained in the presence of an inhibitor. Binding of an inhibitor molecule to the separate 
effector site causes an alteration in Ki by the factor δ (Fig.1.13D and equation 1.11). Where the 
interaction factor δ is > 1, the affinity of the second inhibitor molecule is decreased in the 
presence of the first inhibitor molecule which is consistent with a negative cooperative effect, and 
this effect contributes to the partial inhibition with the increasing inhibitor concentration. The 
concentration and contribution of I(SEI), I(SE), and I(SES) complexes to the [E]t at higher 
inhibitor concentration is increased, but these enzyme species are not productive (Galetin et al., 
2002). 
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Figure 1.13 Multisite kinetic equilibria models for heterotropic cooperativity (Taken from Kenworthy et al., 2001; Geletin et al., 2002:  
A) A generic two-site model; Heterotropic inhibition or activation of a substrate showing hyperbolic kinetics (equation 1.7) and Heterotropic inhibition 
of a substrate with substrate inhibition kinetic (equation 1.8). 
B) Three-site model; Heterotropic inhibition of a substrate showing sigmoidal kinetics (equation 1.9). 
C) Three-site model; Heterotropic activation of a substrate showing sigmoidal kinetics (equation 1.10). 
D) Three-site model; Partial inhibition of a substrate showing sigmoidal kinetics (equation 1.11). 
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Interaction factors Kinetic models Effect on CYP3A4 
α γa δ 
Examples 
 
Heterotropic activation 
 
 
 
1 
 
 
 
> 1 
 
 
 
< 1 
 
 
 
Quinidine effect on diclofenac (Ngui et al., 2000) 
Quinidine effect on warfarin (Ngui et al., 2001) 
Quinidine effect on filodipine and simvastatin (Galetin et al., 2002) 
 
 
Heterotropic inhibition 
 
 
1 
 
 
< 1 
 
 
< 1 
 
 
Haloperidol effect on filodipine and quinidine (Houston et al., 2003) 
 
Two-site model 
 
 
Hyperbolic kinetics 
 
 
 
Partial inhibition  
 
 
 
 
 
1 
 
 
 
 
 
1 
 
 
 
 
 
> 1 
 
 
 
 
Testosterone effect on erythromycin (Wang et al., 1997) 
Testosterone effect on terfenadine (Riedy et al., 2000)  
Testosterone effect on midazolam (Riedy et al., 2000; Houston et al., 2003) 
Nifedipine effect on filodipine (Houston et al., 2003) 
 
 
Substrate inhibition 
 
Heterotropic inhibition 
 
1 
 
 
< 1b 
 
 
< 1 
 
 
Quinidine and haloperidol effect on nifedipine (Galetin et al., 2002) 
Midazolam and filodipine effect on nifedipine (Houston et al., 2003) 
 
 
Heterotropic activation 
 
 
< 1 
 
 
> 1 
 
 
= α 
 
 
Testosterone effect on diazepam (Kenworthy et al., 2001) 
 
 
Heterotropic inhibition 
 
 
< 1 
 
 
1 
 
≤ 1 
 
Diazepam effect on testosterone (Kenworthy et al., 2001) 
Quinidine effect on testosterone (Galetin et al., 2002) 
 
Three-site model 
 
Sigmoidal kinetics 
 
Partial inhibition  
 
 
< 1 
 
 
1 
 
> 1 
 
 
Haloperidol effect on testosterone (Galetin et al., 2002) 
Table 1.3 Multisite kinetic model interaction factors to describe the various modifications of CYP3A4 activity (Modified from Gelatin et al., 2002). 
a β (chang in Kp from SES) = 2 (equivalent binding site); b (β < 1 or β = α) 
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1.2.5.4 Consequences of ignoring atypical kinetics 
 Although atypical behavior is commonly seen in kinetic profiles, it is not always taken 
into account by investigators. Several examples exist of standard Michaelis-Menten hyperbolic 
curves forced through the data rather than the adoption of more suitable models. Here, errors and 
consequences when applied to in vivo clearance prediction may be highly significant (Houston 
and Kenworthy, 2000; Houston and Galetin, 2005). In the case of autoactivation (i.e. sigmoidal 
kinetics; Fig.1.11B), either underestimation or overestimation of the clearance value may occur if 
a hyperbolic curve is forced through the data to obtain the parameters Vmax and Km to calculate the 
in vitro intrinsic clearance (CLint). Typically, underestimation of the CLint results. In this case, the 
CLmax when the enzyme is fully activated represents the alternative to CLint for scaling of in vitro 
data and has been proposed as an alternate scaling strategy (Houston and Galetin, 2003). For 
substrate inhibition, substantial underestimation of Vmax will result from ignoring the high 
concentration data points and forcing a hyperbolic curve through the remaining lower substrate 
concentration points. Furthermore, the Km value will also be poorly estimated (Houston and 
Galetin, 2005). Thus, a full description of the profile (namely, the number and quality of the data 
points) is important if CLint is to be calculated from the Vmax/Km.  
Another important consideration is determination Ki values from inhibition 
studies. Normally, the Ki value is obtained from equations fitted to data that account for the effect 
of various concentrations of inhibitor, including the absence of inhibitor. However, insufficient 
data points to allow examination of the effects of atypical kinetic profiles may result in the 
calculation of an inaccurate Ki value (Houston and Kenworthy, 2000).  
. 
 
 
 
 
  
40 
40
1.2.5.5 Analysis of enzyme inhibition data 
Any substrate that reduces the velocity of an enzyme-catalyzed reaction can be 
considered to be an inhibitor (either irreversible or reversible inhibitor). Irreversible inhibitors 
usually react with the enzyme and change it chemically. These inhibitors modify key amino acid 
residues needed for enzymatic activity. In contrast, reversible inhibitors bind non-covalently and 
different types of inhibition are produced depending on whether these inhibitors bind the enzyme, 
the enzyme-substrate complex, or both. In this section, only reversible inhibition is reviewed. 
There are four types of reversible enzyme inhibitors (Segel, 1993; Ito et al., 1998b; Marangoni, 
2003).   
A-1) Competitive inhibition 
Competitive inhibition arises when the inhibitor competes with the drug for the 
same binding site within an enzyme protein (Fig.1.14).  
 
 
 
 
 
 
 
where E is the enzyme, S is the substrate, ES is the enzyme-substrate complex, P 
is the product, I is the inhibitor, and EI is the enzyme-inhibitor complex. The metabolic rate (ν) 
for this case is shown in summary Table 1.4. A competitive inhibitor acts only to increase the 
apparent Ks (i.e. there is an apparent decrease in the affinity of enzyme for substrate) for the 
substrate without affecting the Vmax values.  
 
 
Figure 1.14 Representative diagram for competitive inhibition.  
(Taken from Marangoni, 2003). 
E + S ES E + P 
+  
I 
EI 
Km 
Ki 
kp 
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A-2) Uncompetitive inhibition 
In uncompetitive inhibition, an inhibitor binds reversibly to the ES complex 
yielding an inactive enzyme-substrate-inhibitor (ESI) complex (Fig.1.15). The inhibitor does not 
bind to the free enzyme.  
 
 
 
 
 
 
 
 
This results in an apparent decrease in both Vmax and Ks (Table 1.4). The 
apparent increase in affinity of the enzyme for substrate (i.e. a decrease in Ks) is due to 
unproductive substrate binding, resulting in a decrease in free enzyme concentration. 
A-3) Noncompetitive inhibition  
Non-competitive inhibition is a pattern of inhibition where the inhibitor binds to 
the same enzyme as the drug but the binding site is different, resulting in a conformational change 
in the protein (Fig.1.16). 
 
 
 
 
 
 
 
 
Figure 1.15 Representative diagram for uncompetitive inhibition. 
(Taken from Marangoni, 2003). 
Figure 1.16 Representative diagram for noncompetitive inhibition. 
(Taken from Marangoni, 2003). 
E + S ES E + P 
+  
I 
ESI 
Km 
Ki 
kp 
E + S ES E + P 
+  
I 
ESI 
Km 
Ki′ 
kp 
+  
I 
EI +S 
Ki 
Km 
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It is assumed that the inhibitor binds to the free enzyme and the ES complex 
with the same affinity. An apparent decrease in Vmax is observed while Ks remains unaffected 
(Table 1.4). 
A-4) Linear mixed inhibition  
This is a form of noncompetitive inhibition, where an inhibitor can interact with 
both the free enzyme and the ES complex at a site other than the active site (Fig.1.16). However, 
the binding of the inhibitor affects the binding of the substrate, and vice versa. Linear mixed 
inhibition includes all of the common types of inhibition as asymptotic or special cases, and it 
will therefore be taken as a general case. It is described by the rate equation:  
 
 
where Ki is the dissociation constant of inhibitor to the enzyme and Ki′ is the 
dissociation constant of inhibitor to the ES complex. An apparent decrease in Vmax and an 
apparent increase in Ks when Ki > Ki′ is observed. In contrast, if Ki < Ki′, both Vmax and Km are 
decreased (Table 1.4). Although it is possible for mixed-type inhibitors to bind in the active site, 
this type of inhibition generally results from an allosteric effect where the inhibitor binds to a 
different site on an enzyme. Inhibitor binding to this allosteric site changes the conformation of 
the enzyme so that the affinity of the substrate for the active site is reduced.  
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Effect on catalytic parameters Inhibition types Rate equations 
Vmax Ks 
Competitive  
 
 
 
No effect 
(↔) 
 
Increase 
(↑) 
Uncompetitive  
 
 
 
 
Decrease 
(↓) 
 
Decrease 
(↓) 
Noncompetitive 
 
 
 
 
Decrease 
(↓) 
 
No effect 
(↔) 
Linear mixed 
 
 
Decrease 
(↓) 
 
Increase 
(↑) 
Linear mixed 
 
 
 
Decrease 
(↓) 
 
Decrease 
(↓) 
 
 
 
 
 
 
 
Table 1.4 Summary of the rate equations describing reversible inhibition and the effects on 
apparent enzyme catalytic parameters (Modified from Bisswanger, 2008). 
υ: Velocity; Vmax: Maximum velocity; [S]: Substrate concentration; [I]: Inhibitor concentration; Km: 
Michaelis–Menten constant; Ki: Dissociation constant of inhibitor to the enzyme; Ki′; Dissociation 
constant of inhibitor to ES complex. 
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To determine visually the type of enzyme inhibition and the Ki values, Dixon 
plots (or direct linear plot) are often used. The effect on the rate of metabolism (υ) is determined 
at two or more substrate concentrations, and over a range of the inhibitor concentration. In a plot 
of 1/ν against [I], data for each inhibitor concentration fall on straight lines and the apparent Ki 
value is obtained from the intercept of all lines. With competitive and mixed inhibition, the lines 
converge above the x axis and the value of inhibitor concentration where they intersect is -Ki 
(Fig.1.17A). For non-competitive inhibition (Fig.1.17B), the lines intersect on the x axis and the 
value of inhibitor concentration where they intersect is -Ki. The lines are parallel in the case of 
uncompetitive inhibition (Fig.1.17C) (Cornish-Bowden, 1974; Segel, 1993; Bisswanger, 2008). 
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Figure 1.17 Representative Dixon plots for different mechanisms of inhibition (Modified 
from Segel, 1993): 
A) Competitive and mixed inhibition. 
B) Non-competitive inhibition. 
C) Uncompetitive inhibition. 
B) 
C) 
υ: Velocity; [S]: Substrate concentration; [I]: Inhibitor concentration; Ki: Inhibitor constant 
1/υ 
1/υ 
A) 1/υ 
  
46 
46
1.2.6 In vitro-in vivo extrapolation (IV-IVE) 
The IV-IVE is an approach that predicts qualitative or quantitative aspects of 
human drug metabolism and kinetics in vivo. At the qualitative level, identification of the 
enzyme(s) responsible for the biotransformation of any given compound allows prediction of 
those factors (e.g. genetic polymorphism, DDIs) likely to influence metabolic clearance (Miners 
et al., 2010). Quantitative prediction most commonly involves the scaling of a CLint calculated 
from the kinetic parameters (Km, Vmax) for formation of metabolite by enzyme sources (either by 
HLM or hepatocytes). The CLint is then scaled up for whole liver by microsome yield (milligrams 
per gram of human liver) and liver weight (normally assumed as 1,500 g) to obtain a whole organ 
of the CLint value, which is subsequently substituted to in vivo hepatic clearance (CLH) using 
expressions for the mathematical models of the CLH (well-stirred, parallel tube, or dispersion 
models) (Fig.1.18) (Pang and Rowland, 1977; Roberts and Rowland, 1986; Houston 1994; 
Iwatsubo et al., 1997; Ito et al., 1998b; Miners, 2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18 Scheme for the extrapolation of the intrinsic clearance (CLint) calculated from human 
liver microsomal kinetic data to hepatic clearance (CLH) in vivo (Taken from Miners et al., 2002). 
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1.13equation          CLCLCLCL otherRHS ++=
1.2.6.1 Prediction of in vivo CLH based on human liver microsomal kinetic data 
A fundamental hypothesis of clinical pharmacokinetics is that a relationship 
exists between the pharmacological effects of a drug and the accessible concentrations of the drug 
in blood or plasma. This hypothesis has been documented for many drugs and is of benefit in the 
therapeutic management of patients. For some drugs, no clear or simple relationship has been 
found between pharmacological effect and concentration in plasma, whereas for other drugs, 
routine measurement of drug concentration is impractical as part of therapeutic monitoring. In 
most cases, the concentration of drug at its sites of action will be related to the concentration of 
drug in the systemic circulation. The pharmacological effect results may be a desired clinical 
effect, a toxic effect or, in some cases, an effect unrelated to therapeutic efficacy or toxicity. 
Clinical pharmacokinetics attempt to provide both a quantitative relationship between dose and 
effect and a framework within which to interpret measurement of concentration of drugs in 
biological fluids. The various physiological and pathophysiological variables that dictate 
adjustment of dosage often do so as a result of modification of pharmacokinetic parameter. The 
four most important pharmacokinetic parameters are clearance, volume of distribution, 
elimination half-life, and bioavailability (Buxton, 2006). 
Clearance (CL) is the most important pharmacokinetic constant. It is defined as 
the proportionality factor relating the rate of drug elimination to the plasma concentration, or the 
volume of blood cleared irreversibly of drug per unit time. The CL may be viewed in another 
way, namely from the loss of drug across an organ(s) of elimination. This latter physiologic 
approach has a number of advantages, particularly in predicting and evaluating the effects of 
changes in blood flow, plasma protein binding, enzyme activity, or secretory activity on the 
elimination of a drug. The CL value can be considered in terms of the organs of elimination, 
namely hepatic clearance (CLH), renal clearance (CLR), pulmonary clearance, etc. The sum of the 
individual organ clearance values is equal to the systemic clearance (CLS), which is whole body 
clearance (equation 1.13). 
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 where CLH is hepatic clearance, CLR is renal clearance and CLOther is clearance 
by all other routes. Although drug metabolism can take place in many organs, the liver has the 
greatest metabolic capacity and consequently has been the most thoroughly studied. The CLH is 
often expressed as the blood flow rate multiplied by the extraction ratio (equation 1.14).  
 
where QH is the sum of hepatic portal and hepatic arterial blood flow 
(approximately 90 L/hr for a healthy adult) (Coleman, 2005) and EH is the hepatic extraction ratio 
which represents the difference between the drug concentration in blood that enters the liver (Ca) 
and the concentration of drug in blood leaving the liver (Cv) according to the following equation: 
 
The term of EH is dimensionless and ranges between 0 and 1 (sometimes 
expressed as a percent). EH = 0 means that the liver does not remove drug at all during perfusion, 
whereas EH = 1 indicates the complete elimination of a drug from the blood by the liver during 
perfusion. In other words, EH reflects the liver’s efficiency in removing drug from the blood 
stream.  
A-1) Hepatic clearance models 
The IV-IVE approach is based on two essential steps (Fig.1.18). The initial step 
is conversion of the units of the CLint to a parameter expressed in terms of total liver weight. The 
second step is incorporation other physiological processes (blood flow and blood protein binding) 
with the intrinsic metabolic stability of a drug to provide a whole liver CLH (Houston 1994; Ito 
and Houston, 2004). Thus, the use of hepatic clearance models is an essential step in the scaling 
process and is used to relate the clearances obtained in vitro to the in vivo situation. There are 
three hepatic models which have been used: the well-stirred, parallel tube, and dispersion models 
(Ito and Houston, 2004). These models differ in their physiological interpretation of the way in 
which drugs interact in the liver (Pang and Rowland, 1977). Differences between these models 
have been extensively discussed and the application of different models to the same set of 
experimental data has been performed (Ito and Houston 2004). Result showed that different 
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models give acceptably similar clearance values. However, because well-stirred model is 
mathematically less cumbersome, it has been more widely applied in IV-IVE approach (Pelkonen 
and Turpeinen, 2007). 
 The well-stirred model assumes that the entire liver tissues including 
hepatocytes and the blood in the sinusoid, are well mixed so that drug molecules are distributed 
instantaneously and homogeneously within the liver. As a result, the drug concentration within 
the liver is assumed to be equal throughout the organ. In other words, the well-stirred model 
views the liver as a single compartment (anatomy of the liver) with complete mixing of blood 
(extent of blood mixing). Important assumptions for the well-stirred model for CLH include (Pang 
and Rowland, 1977; Kwon, 2002): a) only unbound drug in blood is subject to elimination 
(metabolism and/or biliary excretion), b) no membrane transport barrier, c) no concentration 
gradient of the drug within the liver, d) concentration of the drug within the liver is equal to that 
in emergent venous blood, and e) linear kinetics.   
The CLH based on the well-stirred model is described as follows:  
 
where CLint is the intrinsic clearance, a measure of the efficiency of the 
metabolic enzymes, and ƒu is fraction unbound concentration in blood which is calculate by 
equation 1.17: 
 
where ƒu,p is the fraction of a drug unbound in plasma and RB is the blood to 
plasma concentration ratio which is calculated by equation 1.18. 
 
where Cb and Cp are the drug concentrations in blood and plasma, respectively. 
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A-2) Determination of unbound concentration 
In general, when drug enters into blood, most of the drug equilibrates rapidly 
with blood constituents such as blood cells, albumin, and α1-acid glycoprotein. Binding of a drug 
to plasma and tissue proteins is a saturable process, and is generally considered reversible with 
rapid equilibrium within milliseconds. Albumin and α1-acid glycoprotein are the two major 
proteins in plasma, with albumin being by far the most abundant (approximately 4% w/v) (Kwon, 
2002). Three conventional methods are used for measuring the unbound drug concentration in 
plasma; equilibrium dialysis, ultrafiltration, and ultracentifugation (Oravcova et al., 1996). 
Comparison of these methods is shown in Table 1.5. Of these, equilibrium dialysis and 
ultrafiltration are the most widely used because of their simplicity and general applicability to 
many different systems in vitro including plasma, serum, or tissue homogenate. However, 
equilibrium dialysis is often regarded as a “reference method” for the determination of drug 
protein binding, although this method has several problems which are summarized in Table.1.5. 
The adsorption of drugs to the surface of the dialysis device and dialysis membrane is a potential 
problem, particularly for highly lipophilic drugs: for example, for cyclosporin the use of steel 
chambers has been reported, instead of Teflon or Perspex cells which exhibit extensive adsorption 
(98%) of this compound (Henricsson, 1987). In addition, the observed unbound fraction may be 
overestimated as a result of slight leakage of protein into the dialysis apparatus, and thus the 
absence of drugs should be confirmed by protein assay in a validation study (Oravcova et al., 
1996). 
Equilibrium dialysis is based on the establishment of an equilibrium state 
between a protein compartment and buffer compartment (McLure et al., 2000; Kwon, 2002). The 
equilibrium dialysis chamber for the binding compartment contains the drug and protein, from 
tissue homogenate, plasma, albumin etc. The other chamber contains buffer alone. Both chambers 
are separated by a semipermeable membrane which allows only low-molecular-weight ligands, 
such as drug molecules, to distribute between the two sides. Sodium or potassium phosphate 
buffers at pH 7.4 are most commonly used, although other buffers for some compounds are 
required due to the formation of insoluble salts or interactions with drug binding sites in protein 
molecules. When equilibrium is reached after incubation, only unbound drugs diffuse across the 
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semipermeable membrane. The fraction unbound of drug in incubation (ƒu,inc) is calculated 
according to equation 1.19:  
 
where Cb* and Cp* denote the concentrations of compound in the dialysis 
chambers containing buffer and protein, respectively.  
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 Equilibrium dialysis Ultrafiltration Ultracentrifugation 
Advantages 
 
 
 
- Temperature controlled 
- Thermodynamically sound 
- Considered as standard method 
- Need small amount of sample (< 1 mL) 
- Fast ( take ~ 30 min) 
- No buffer need 
- Commercially available kit 
- Disposable device 
- Small changes in drug concentration 
during filtration 
- No Donnan effect 
- No  nonspecific binding of drug to 
apparatus  
Disadvantages - Long time to reach equilibrium (up to 20 hr) 
- Need of buffer 
- Degradation of unstable compound 
- Donnan effect in buffera 
- Volumn shiftb 
- Dilution of drugc 
- pH change 
- Nonspecific binding to dialysis device and 
membrane 
- Nonspecific binding of drug to plastic 
tube or ultrafiltration membrane  
- Volume of ultrafiltrate may not be 
sufficient for drug assay 
- Usually not temperature controlled 
- Constriction of membrane pores during 
ultrafiltration 
- Donnan effect  
- Long time to reach equilibrium (12-15 hr) 
- Need large amount of sample (> 1 mL) 
- Usually not temperature controlled 
- Binding equilibrium may be altered during 
separation process (sedimentation, back 
diffusion) 
- Expensive equipment 
 
Applications - More suitable for highly protein bound 
drugs (> 98%) 
- Suitable for fast screening when 
nonspecific binding is less than 10% 
- More applicable for highly concentrated 
protein solution or tissue homogenates 
- An alternative method to eliminate the 
effect of nonspecific binding to dialysis 
apparatus 
Table 1.5 Comparison of conventional separation methods (Modified from Oravcov et al., 1996 and Kwon, 2002). 
a The observation that charged molecules starting on one side of a semipermeable membrane sometimes will not evenly distribute themselves by diffusion on both sides of the 
membrane. 
b Owing to the osmotic pressure difference between plasma (high) and buffer (low), water molecules from the buffer side are continuously moving into the plasma side during 
incubation, causing an increase in plasma volume and a decrease in buffer volume as compared to the original values. 
c The initial concentration of drug in plasma decreases during incubcation as the plasma and the buffer equilibrate. Equilibrium dialysis may be inappropriate when there are significant 
changes in the extent of protein binding of a drug resulting from its dilution in plasma with buffer during equilibrium. 
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A-3) Reasons for the underestimation of in vivo CLH 
Although IV-IVE has an enormous potential, the promise is yet to be met. The 
use of HLM as the enzyme source generally results in underestimation of the in vivo CLH. Several 
studies have compared observed and predicted in vivo CLint values based on kinetic data 
generated using HLM and cryopreserved human hepatocytes. These datasets include drugs 
metabolized by CYP and UGTs (Ito and Houston, 2005; Riley et al., 2005; Brown et al., 2007). 
Riley et al. (2005) showed that underestimation of in vivo CLint with HLM as the enzyme source 
is consistent with the underestimation of in vivo CLH (Table 1.6).  
 
 
 
 
aIn vivo CLint,un (mL/min/kg) Compounds 
Predicted Observed 
% Underestimation References 
Amitriptyline 
Diazepam 
Diclofenac 
Ibuprofen 
Imipramine 
Metoprolol 
Methoxsalen 
Nilvadipine 
Omeprazole 
Phenacetin 
Phenytoin 
Propranolol 
Quinidine 
Verapamil 
Zolpidem 
94.3 
8.3 
190.9 
10.6 
106.6 
6.8 
43.0 
3867 
101.0 
9.9 
0.5 
16.3 
10.7 
286.6 
31 
516.0 
33.8 
1348.4 
89.2 
330.0 
20.2 
1340.0 
8123.4 
502.7 
212.5 
4.0 
284.5 
22.1 
2926.0 
155.3 
81.72 
75.44 
85.84 
88.12 
67.70 
66.34 
96.79 
52.40 
79.91 
95.34 
87.50 
94.27 
51.58 
90.21 
80.04 
(Obach, 1999) 
(Obach, 1999) 
(Obach, 1999) 
(Obach, 1999) 
(Obach, 1999) 
(Obach, 1999) 
(Riley et al., 2005) 
(Naritomi et al., 2001) 
(Naritomi et al., 2001) 
(Riley et al., 2005) 
(Carlile et al., 1999) 
(Riley et al., 2005) 
(Obach, 1999) 
(Obach, 1999) 
(Naritomi et al., 2001) 
Table 1.6 Correlation between predicted and observed in vivo CLint,un values for drugs 
metabolized CYP and UGT from some of studies (Modified from Riley et al., 2005). 
a in vivo intrinsic clearance corrected for  the fraction unbound in incubation 
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The reasons for the underestimation regarding to in vivo CLint or in vivo CLH are 
still unclear; however, there are numerous factors involved as discussed in the following sections. 
Underestimation arising from the IV-IVE approach may result from physiological scaling factors, 
non-specific and protein binding, inappropriate kinetic modeling in vitro, metabolism by 
extrahepatic tissues, etc. In addition, incubation components such as buffer type, pH and ionic 
strength, and the presence of activators, e.g. alamethicin, detergents, Mg2+ or other treatments 
(e.g. sonication), may result in variability (Miners et al., 2004, 2006, and 2010).  
a) Physiological scaling factor 
In general, the CLint obtained in vitro using microsomes fresh or cryopreserved 
hepatocytes, precision-cut liver slices or recombinant enzymes is converted to in vivo CLH using 
physiological scaling factors. The physiological scaling factors for data from liver microsomes, 
hepatocytes, homogenates and liver slices are milligram of microsomal protein per gram of liver 
(MPPGL), number of hepatocytes per gram of liver (HPGL; hepatocellularity), milligram of 
homogenate protein per gram of liver (HomPGGL) or slice mass, respectively. A combination of 
MPPGL together with hepatic enzyme abundance is used to scale data from recombinantly 
expressed enzyme systems (Fig.1.19) (Barter et al., 2007). Although several different enzyme 
sources may be used for IV-IVE, HLM is normally employed. Different values for MPPGL have 
been used over the years, many of them based on rat data. For example, the value of 45 mg/g 
commonly used for human MPPGL is determined originally from studies with rat hepatic 
microsomes (Houston, 1994). Recently, Barter et al. (2007) collated and analyzed data from a 
number of sources to provide weighted geometric mean values of human MPPGL of 32 mg/g 
(95% confidence interval in range 29–34 mg/g). Another publication gives a similar value 
(Hakooz et al., 2006). Scaling of the liver unit value to the whole organ requires a value for liver 
weight. A value of 1,500 g in man has usually been employed, although there are recent meta-
analyses on the liver size in different ethnic population (Murry et al., 1995; Urata et al., 1995; 
Heinemann et al., 1999; Johnson et al., 2005). Values derived from these studies are sufficiently 
similar to the above value so that scaling to the whole organ can reasonably be performed 
assuming the liver weight as 1,500 g (Pelkonen and Turpeinen, 2007).  
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b) Nonspecific and protein binding 
Nonspecific binding of substrate to incubation components, including 
microsomes, hepatocytes, or albumin added to incubation mixtures, is a very important factor in 
the calculation of kinetic constants for drug metabolism reactions in vitro. Failure to account for 
this phenomenon may lead to overestimation of Km and, hence, underestimation of CLint (Table 
1.6) (Ito et al., 1998a; Miners et al., 2004). Some investigations have shown that the CLint values 
of certain lipophilic amines (e.g. propranolol and imipramine) with high plasma protein binding 
or low unbound fractions in plasma (ƒu,p ≤ 0.1) are very poorly predicted (up to 100-fold). When 
plasma blood binding values are removed from hepatic models (well-stirred or parallel tube 
models) for these compounds, scaled-up values of CLint are sometimes close to those measured in 
vivo (Obach, 1996, 1997). It is thus frequently assumed that non-specific binding in vitro and 
protein binding in vivo ‘cancel out’, and hence both terms are not uncommonly ignored in the 
Figure 1.19 Schematic representation of the scaling procedure using different in vitro systems. 
(Modified from Barter et al., 2007). 
In vitro CLint Liver slices Hepatocytes Liver 
microsomes
Recombinant 
enzymes
Rate per functional 
unit of systems
pmol.min-1.g-1 
slice
pmol.min-1.mg-1 
total proteins
pmol.min-1.10-6
cells-1 
pmol.min-1.pmol 
CYP isoform-1
pmol.min-1.mg 
microsomal
protein-1
Scaling factor 1
HomPPGLa HPGLb MPPGLc x CYP isoform
(pmol.mg-1)
MPPGL
Rate per gram of 
liver
Scaling factor 2 Liver weight (g)
In vivo CLH
(ul/min)
a Milligrams of homogenate protein per gram of liver, b Hepatocellularity per gram of liver, c Milligrams of 
microsomal protein per gram of liver. 
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calculation of in vivo CLH (Obach, 1999; Riley et al., 2005; Miners et al., 2006). However, the 
two parameters are not related in a linear manner (Ito and Houston, 2005) and inclusion of both 
microsomal and plasma protein binding usually results in a better agreement between extrapolated 
and actual clearance values (Obach, 1999; Riley et al., 2005; Miners et al., 2006). Importantly, 
determination of fraction unbound of drug in a biological matrix (microsomal incubations, plasma 
etc.) can easily be measured by several methods as describe above and should therefore be 
accounted for in IV-IVE. 
c) Incubation conditions  
Difference of incubation conditions with HLM as the enzyme source may result 
in underestimation of CLint, Km and Vmax values for glucuronidation. It can vary with buffer type, 
pH and ionic strength, and the presence of activators (e.g. alamethicin, detergents, Mg2+) or other 
treatments (e.g. sonication) which release the ‘latency’ of microsomal UGTs (Boase and Miners, 
2002; Soars et al., 2003; Engtrakul et al., 2005). Buffer type and strength for UGT assays with 
HLM as the enzyme source vary significantly among different laboratories. Several groups use 
phosphate buffers (Fisher et al., 2000; Boase and Miners 2002; Court et al., 2003), whereas others 
groups use sucrose buffer (Bock et al., 1984; Soars et al., 2001). Soars et al. (2003) showed that 
the formation of estradiol-3-glucuronide is up to 2.5-fold greater using HLM prepared in 
phosphate buffer compared with those prepared in sucrose with all other assay components held 
constant. In contrast, rates of AZT glucuronidation by HLM have been shown to be 
approximately doubled in the presence of carbonate buffer when compared to incubations 
performed in phosphate buffer (Engtrakul et al., 2005), but the rate is no difference between 
phosphate and Tris-buffered incubations (Boase and Miners, 2002). Additionally, the pH and 
Mg2+ content of buffers may result in different rates of drug glucuronidation (Boase and Miners 
2002; Soars et al., 2003).  
Activation by the membrane pore-forming peptide (alamethicin), sonication, or 
Brij 58 (polyoxyethylene monocetyl ether) have been shown to be necessary for optimum 
enhancement of microsomal UGT activity (Fisher et al., 2000; Boase and Miners, 2002; Soars et 
al., 2003). The consistently high levels of activation obtained using the alamethicin (Fig.1.20) and 
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C92H150N22O25 
(MW. 1964.4) 
its ease of use (50 μg/mg protein always gave maximal activation) provides a universal alternative 
to detergents for overcoming the latency of all UGT forms and achieving maximal 
glucuronidation activity in liver microsomes (Fisher et al., 2000; Soars et al., 2003). This latency 
arises from the location of the active site of UGTs within the lumen of the ER, such that the ER 
membrane presents a diffusional barrier for the access of substrates and cofactors to the enzyme 
(Meech and Mackenzie, 1997). Disruption of this barrier is required to overcome enzyme latency 
and obtain maximal glucuronidation activity in microsomal incubations.  
 
  
 
  
  
  
  
   
  
  
 
  
  The mechanism of alamethicin insertion into the membrane to form well-defined pores 
has been elucidated (He et al., 1996). Thus, the alamethicin allows free diffusion of substrates, 
cofactors, and products without affecting the gross membrane structure and intrinsic enzyme 
catalytic activity (Fisher et al., 2000). In addition, enhancement the microsomal UGT activity 
may be seen with Mg2+ occurring in the presence of pores formed with alamethicin, when free 
diffusion of substrates and products occurs. Therefore, the Mg2+ appears to exert its effects 
directly on the actual catalytic activity of the UGTs increasing their catalytic activities (Fisher et 
al., 2000; Boase and Miners 2002). 
 
 
Figure 1.20 Structure of alamethicin  
(Taken from Jones et al., 1980). 
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d) Extrahepatic metabolism 
Underestimation of CLint may also result from extrahepatic metabolisms. As 
mentioned previously, UGTs are expressed in tissue other than liver. Apart from the liver, 
UGT1A3, 1A9, and 2B7 are expressed in kidney and multiple forms are expressed throughout the 
GI tract (Tukey and Strassburg, 2000). Several lines of evidence showed that UGT activity is 
readily measurable in human kidney and GI tract and this has led to the proposal that these organs 
contribute significantly to the systemic clearance and first-pass extraction, respectively, of 
glucuronidated drugs (Soars et al., 2001 and 2002; Miners et al., 2004; Tsoutsikos et al., 2004; 
Knights and Miners, 2010). Recently, evidence showed that the small intestine can contribute to 
first-pass metabolism in humans and thus lead to significant of extrahepatic drug glucuronidation 
(Soars et al., 2002; Galetin et al., 2002). Ethinylestradiol is one example. The CLint value is 2- to 
3-fold greater with human intestinal microsome (HIM) than the CLint determined with HLM. 
Similarly, small intestinal activity is higher than hepatic microsomal activity for the UGT1A1 
probe estradiol (Czernik et al., 2000; Fisher et al., 2001). Additionally, glucuronidation by human 
kidney microsome (HKM) is predicted to be important in the metabolism of several compounds 
(Knights and Miners, 2010).  
e) Atypical kinetic behaviors 
There is also increasing evidence that many compounds metabolized by 
glucuronidation via UGT enzymes exhibit ‘atypical’ or non-Michaelis-Menten kinetic behavior 
(Miners et al., 1988; Uchaipichat et al., 2006a; Wong et al., 2007). Atypical kinetics clearly 
impact on IV-IVE approaches which are assumed to be hyberbolic (Michaelis-Menten) kinetics. 
The consequences of ignoring atypical kinetic have been described as above.        
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1.2.6.2 Prediction of inhibitory interactions involving glucuronidated drugs from in vitro 
kinetic data 
 
DDIs caused by inhibition of metabolic enzymes are common and clinically 
important. Despite the success of the IV-IVE approaches for drugs eliminated by CYP, few 
studies have investigated the reliability of extrapolating human liver microsomal kinetic data to 
an in vivo CLH for drugs metabolized by glucuronidation. The UGTs is quantitatively the most 
important conjugation enzyme, and drugs from all therapeutic classes are eliminated by 
glucuronidation (Miners and Mackenzie, 1991). The effects of inhibition of drug metabolism on 
in vivo pharmacokinetics are highly variable and depend on the properties of the drug, the route 
of administration, etc. (Rowland and Matin, 1973; Tucker, 1992). Lack of a good understanding 
of the underlying inhibition mechanism may lead to inappropriate experimental design and 
inaccurate estimation of Ki values (Lin, 2000). 
A-1) Equations for the quantitative prediction of in vivo DDIs 
In human in vivo interaction studies, the degree of interaction is expressed as the 
ratio of the AUC in the presence and absence of an inhibitor (Miners et al., 2010). The AUC ratio 
is related to the ratio of the CLint. The degree of inhibition depends on the inhibition pattern when 
the substrate concentration is high. However, when the substrate concentration is much lower 
than Km (Km>>[S]), and the mechanism of inhibition (competitive or noncompetitive) is not 
relevant; therefore, the following equation (equation 1.20) is valid for both inhibition types 
(Tucker, 1992; Ito et al., 1998b): 
 
where [I] is the concentration of inhibitor at the enzyme active site; ƒm is the 
fraction of the dose metabolized by the enzyme and pathway of interest, and Ki is the inhibitor 
constant generated in vitro.  
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A-2) Estimation of inhibitor concentration at the enzyme active site 
The accuracy of DDIs potential is optimized when [I] is taken as the maximum 
hepatic inlet concentration (Iinlet) (Miners et al., 2010). Ito et al. (1998a) proposed an approach for 
predicting in vivo drug interaction potential using the concept of the unbound inhibitor hepatic 
inlet concentration (Iinlet,u), where the blood flow from the hepatic artery and portal vein meet. The 
Iinlet,u of a given inhibitor during absorption can be expressed as a following equation. 
 
 
where QH and ƒu are the hepatic blood flow and the unbound fraction of 
inhibitors in blood, respectively. ka and Fa represent the first-order absorption rate constant and 
the fraction of oral dose absorbed from the GI tract into the portal vein, respectively. During oral 
absorption, the concentration of inhibitor presented to hepatocytes via the portal vein is 
significantly higher than the systemic circulation, depending on the rate and extent of absorption. 
As indicated in the above equation, the first term of the equation, Imax (the maximum inhibitor 
concentration in the hepatic artery and portal vein), represents the contribution from systemic 
circulation, and the second term [(ka × Fa × Dose)/QH] is the contribution from the absorption. 
Because of practical limitations in the measurement of inhibitor concentration in the portal vein in 
humans, Ito et al. (1998b) also proposed that the ka and Fa values can be used to estimate the 
inhibitor concentration in the portal vein. The parameters (Imax, Fa, and ƒu) of inhibitors can be 
obtained from clinical studies, and the ka values of inhibitors can be indirectly calculated from the 
time to maximum drug concentration (Tmax) and absorption half life in plasma (t1/2,ab). With this 
approach, there is an implicit assumption that a rapid equilibrium occurs between blood and 
hepatocytes. However, in vivo clinical studies frequently do not report ka values; therefore, the 
theoretical maximum value of 0.1 min-1 is frequently used for ka. Generally, the ka value of the 
orally administered drug is maximum when the GI absorption of the drug is so rapid that the rate 
limiting step is the gastric emptying rate (Ito et al., 1998b).  
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1.2.7 Albumin 
Serum albumin is the most abundant blood plasma protein and is produced in the 
liver. It comprises a large proportion of all plasma proteins. Human serum albumin (HSA) 
accounts for approximately 60% of all human plasma proteins and circulates in the blood at a 
concentration of approximately 640 μM (or 4% w/v) (Zunszain et al., 2003).  
1.2.7.1 Structure of human serum albumin 
The HSA (Fig.1.21) is a helical protein of 66 kDa which contains three 
homologous domains, I (residues 1-195), II (196-383), and III (384-585), each of which is 
composed of a and b subdomains (He and Carter, 1992). Although all three domains of the HSA 
molecule have similar three-dimensional structures, their assembly is highly asymmetric. Domain 
I and II are almost perpendicular to each other to form a T-shaped assembly in which the tail of 
subdomain IIA is attached to the interface region between subdomain IA and IB by hydrophobic 
interactions and hydrogen bonds (Sugio et al., 1999; Zunszain et al., 2003).  
 
 
 
 
 
 
 
 
 
 
Figure 1.21 Crystal structure of human serum albumin.  
(Taken from Sugio et al., 1999). 
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In contrast, domain III protrudes from subdomian IIB at an angel of about 45°C 
to form a Y-shaped assembly for domains II and III. Domain III interacts only with subdomain 
IIB. These features make the HSA molecule heart-shaped (Sugio et al., 1999; Zunszain et al., 
2003). In addition, several investigators have shown that HSA has a high affinity for a very wide 
range of substances, including metals such as Cu2+ and Zn2+, fatty acids, and many drugs. The 
possible binding sites of long chain fatty acids are located at the surface of all three domains and 
Arg117, Lys351, and Lys365 may be binding sites for long chain fatty acids (Sugio et al., 1999). 
1.2.7.2 Function of albumin 
Albumin is essential for maintaining the oncotic pressure in the vascular system. 
A decrease in oncotic pressure due to a low albumin levels allows fluid to leak out from the 
interstitial spaces into the peritoneal cavity, producing ascites. Albumin is also very important in 
the transportation of many substances such as drugs, lipids, hormones, and toxins that are bound 
to albumin in the bloodstream. Once the drug or other substance reaches the liver, it may 
dissociate from albumin and made less toxic by conversion to a water-soluble form that can be 
excreted. 
1.2.7.3 Effect of albumin on in vitro kinetic parameters 
Although predictivity using HLM as the enzyme source is good for some drugs 
metabolized by CYP, there is a general trend to underestimation of CLH as mentioned above. 
Similarly, in vitro Ki values generated using HLM or recombinant human UGT2B7, underpredict 
the magnitude of inhibitory drug interactions (Rowland et al., 2006; Uchaipichat et al., 2006b).  
Results from previous studies have shown that addition of BSA to HLM incubations decreases the 
Km and increases the in vitro CLint for drugs metabolized by CYP2C9 (Tang et al., 2002; Wang et 
al., 2002; Zhou et al., 2004). Improved predictivity of in vivo CLint values occur for experiments 
conducted in the presence of BSA. Furthermore, the addition of 2% BSA to incubations of HLM 
and recombinant UGT2B7 increases the in vitro CLint for LTG and AZT glucuronidation 7 to 10-
fold and reduces the Ki (Rowland et al., 2006; Uchaipichat et al., 2006b).  
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Recently, it has been shown that several unsaturated long-chain fatty acids are 
present in HLM, human embryonic kidney (HEK293) cell lysates, and some albumin preparations 
(Rowland et al., 2007). Oleic, linoleic, and arachidonic acids are the most prevalent (Rowland et 
al., 2007). Studies have demonstrated previously that oleic, linoleic and arachidonic acids are 
substrates of UGT2B7 (Jude et al., 2001; Turgeon et al., 2003; Little et al., 2004); therefore, fatty 
acid glucuronides can be formed during incubation and released during the course of incubation. 
Furthermore, these fatty acids have been shown to inhibit UGT2B7 activity, with arachidonic acid 
the most potent fatty acid inhibitor of UGT2B7 identified to date (Tsoutsikos et al., 2004). 
Addition of BSA into incubations has the capacity to sequester inhibitory fatty acids, and 
subsequently reverses the inhibition (Rowland et al., 2007). In contrast to BSA, UGT activity is 
not improved in the presence of HSA. Rowland et al. (2007) indicated that this may be due to the 
fatty acid content (oleic, linoleic, and arachidonic acids) of HSA preparations which are 
significantly higher than in BSA. Therefore, it is also likely that HSA contributes fatty acids to 
the incubation mixture. Because fatty acids can desorb from binding sites on albumin despite high 
binding affinities, fatty acid glucuronide formation is enhanced for incubations conducted in the 
presence of HSA (Hamilton, 2002; Rowland et al., 2007). 
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Figure 1.22 Chemical structure of codeine. 
(Taken from Williams et al., 2001). 
H
H
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1.2.8 Codeine 
COD or 7, 8-didehydro-4,5-epoxy-3-methoxy-17-methyl-morphinan-6-ol mono-
hydrate (Fig.1.22) is a naturally occurring opium alkaloid (Reynolds, 1996). It was first 
discovered as a natural constituent of opium in very small concentrations, in the range of 0.7%-
2.5% by weight. Most COD found in pharmaceutical products today is synthetically produced via 
the methylation of morphine. COD effloresces slowly in dry air and is affected by light (William 
et al., 2001).   
 
 
 
 
 
   
 
1.2.8.1 Pharmacodynamics 
COD is mainly used as an analgesic, but is also employed as an antitussive agent 
and antidiarrhoeal (Eriksson et al., 1982; Dollery, 1999). It is less potent than morphine, with a 
potency ratio of 1:10 (Wallenstein et al., 1961). COD can be administered per orally (PO), 
subcutaneously (SC), intramuscularly (IM) and per rectally (PR). COD can not be safely 
administered by an IV injection as it may result in pulmonary oedema, facial swelling, release of 
histamine, and various cardiovascular effects (Parke et al., 1992). COD is often used in 
combination with other drugs, for examples aspirin, paracetamol, NSAIDs and diphenhydramine 
in the treatment of mild to moderate pain. In neonates and children, it has been used in both acute 
and chronic painful conditions and particularly for post-operative and cancer pain (de Lima et al., 
1996). Its antitussive and constipating properties also mean that it is used in many cough, cold 
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and antidiarrhoeal remedies. However, both adult and pediatric clinical studies have demonstrated 
that the efficacy of COD is low and it has a ceiling effect at higher doses above which there is a 
marked increase in the incidence of side-effects (Quiding et al., 1993; McEwan et al., 2000). 
A-1) Mechanism of actions 
Analgesic effect: COD is a weak opioid agonist in the CNS. It has low affinity 
for the opioid receptor and the analgesic activity of COD is due to its conversion to morphine 
(Sindrup and Brosen, 1995; William et al., 2001). Opioid agonist produces analgesia by binding 
to specific G protein-coupled receptors, mu (μ), kappa (κ), and delta (δ), located primarily in the 
brain and spinal cord regions involved in the transmission and modulation of pain. COD binds to 
the μ receptor like morphine but with a much lower affinity. It also binds to κ and δ receptors but 
again has a much lower affinity than morphine, though the difference is less marked (Neil, 1984). 
Opioids do not alter the pain threshold of afferent nerve endings to noxious stimuli, nor do they 
affect the conductance of impulses along peripheral nerves. Analgesia is mediated through 
changes in the perception of pain at the spinal cord and higher levels in the CNS. The stimulatory 
effects of opioids are the result of 'disinhibition' as the release of inhibitory neurotransmitters such 
as γ-aminobutyric acid (GABA) and acetylcholine is blocked. The exact mechanism how opioid 
agonists caused both inhibitory and stimulatory processes is not well understood. Possible 
mechanisms for these processes include differential susceptibility of the opioid receptor to 
desensitization or activation of more than one G-protein system or subunit (one excitatory and 
one inhibitory) by an opioid receptor. 
Antitussive effect: The antitussive effect of COD is mediated through direct 
actions on receptors in the cough centre of the medulla. COD also has a drying effect on the 
respiratory tract and increases the viscosity of bronchial secretions. Cough suppression can be 
achieved at lower doses than those required to produce analgesia (Sindrup and Brosen, 1995). 
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A-2) Adverse effects and toxicity 
Common adverse drug reactions associated with the use of COD include itching, 
nausea, vomiting, drowsiness, dry mouth, miosis, orthostatic hypotension, urinary retention and 
constipation (Eckhardt et al., 1998). A potentially serious adverse drug reaction, as with other 
opioids, is respiratory depression which is dose-related. This effect is the mechanism for the 
potentially fatal consequences of overdose. Another adverse effect is the lack of sexual drive. 
COD toxicity may occur in overdose. The clinical course is complicated by shock, respiratory 
arrest and laboratory evidence of acute hepatic insufficiency. An initial slow rate of COD 
metabolism, possibly related to the hepatic damage, corresponds to prolonged respiratory 
depression (Huffman and Ferguson, 1975).  
According to the incidence and role of COD in drug-related deaths in Victoria, 
Australia, a total of 107 cases were investigated over a 5-year period (Gerostamoulos et al., 
1996). There were six fatalities in which COD was considered the major poison and the 
remaining 101 cases involved a combination of COD and other drugs. The most common drugs 
have found in this group, other than COD, are acetaminophen (62%), diazepam (46%), salicylates 
(20%), and ethanol (25%). The association of other psychoactive drugs in these deaths made the 
contribution of COD is difficult to assess. Free COD concentrations > 0.4 mg/L and total COD 
concentrations > 2.0 mg/L may be sufficient to cause death in the absence of any other 
contributing factors.  
More recently a case of drug-induced hypersensitivity syndrome which relates to 
COD has been reported (Enomoto et al., 2004). A Japanese patient was prescribed COD 
phosphate 3 times daily and several other drugs for cold symptoms. About 20 days later, an 
erythematous, maculopapular rash appeared and progressed to erythroderma (a spiking fever). 
Laboratory examinations have showed atypical lymphocytosis, eosinophilia, and increased liver 
enzyme values. The platelet count slowly decreased after admission. However, although COD 
may rarely be associated with hypersensitivity syndrome, clinicians should be aware that the 
potentially fatal syndrome can be caused by various drugs. 
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1.2.8.2 Pharmacokinetics 
COD is rapidly and well absorbed following PO administration, although 
approximately 50% undergoes presystemic metabolism in the gut and liver. Peak plasma 
concentration occurs after approximately 1 hr and the plasma half-life is 3-3.5 hr. Absorption is 
faster after IM injection, the time to peak plasma concentration is about 0.5 hr. The volume of 
distribution is 3.6 L/kg and the clearance is as high as 0.85 L/min (Dollery, 1999). COD has a 
medium to high hepatic extraction ratio (from 0.52 to 0.83) which is apparently dose-dependent 
(Christensen et al., 1984). PR administration of COD has been recently introduced into pediatric 
practice. A study in healthy adult volunteers has showed no difference in COD bioavailability 
following PR or PO administration with a systemic availability of about 90% (Moolenaar et al., 
1983). Plasma protein binding is small (7-25%) (Moffat et al., 1986). Elimination occurs mainly 
in renal as the unchanged drug, norcodeine, and free and conjugated morphine. Negligible 
amounts are excreted in the feces (Chen et al., 1991; Vree et al., 2000). 
COD is considered a prodrug, since it is metabolized in vivo to morphine 
(Srinivasan et al., 1997; Vree et al., 2000). Roughly 5-10% of COD will be converted to 
morphine, with the remainder either free or conjugated to C6G (~80%) or converted to 
norcodeine (~10%) (Vree et al., 2000). The metabolic pathway is presented in Figure 1.23.  
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Figure 1.23 Metabolic pathway of codeine.  
(Modified from Vree et al., 2000). 
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The major metabolic pathway of COD is the formation of the C6G metabolite by 
UGT2B7 and possibly UGT2B4 (Court et al., 2003). The COD is metabolized to a minor extent 
via O-demethylation by CYP2D6 to morphine and via N-demethylation by CYP3A4 to 
norcodeine (Yue et al., 1989; Chen et al., 1991; Vree and Verwey-van Wissen, 1992). 
Norcodeine and morphine are subsequently glucuronidated to the corresponding 3-and 6-
glucuronides. Only 10% of COD is not metabolized but is essential for its opioid activity (Vree 
and Verwey-van Wissen, 1992). 
 
1.3 Objectives 
This study aims to quantitatively predict the in vivo COD glucuronidation and 
inhibition using the in vitro kinetic parameters. The objectives are as follows: 
1.3.1 To investigate whether the in vitro kinetic parameters (Km, Vmax, CLint) 
determined for the COD glucuronidation, using HLM, predict the COD glucuronidation in vivo. 
1.3.2 To determine the COD glucuronidation by recombinant UGT enzymes 
(viz. UGT2B4 and UGT2B7). 
1.3.3 To investigate the effect of VPA on COD glucuronidation in HLM. 
1.3.4 To predict the magnitude of inhibitory interaction of COD glucuronidation 
by FLZ, KTM, and KTZ in vivo. 
1.3.5 To investigate the effect of exogenous albumin on the kinetics of COD 
glucuronidation and inhibition in vitro. 
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CHAPTER 2 
METHODOLOGIES 
2.1 Materials and chemicals 
Codeine (COD), codeine-6-glucuronide (C6G), bovine serum albumin (‘crude’ 
BSA, 98-99% albumin, product number A7906), alamethicin (from Trichoderma viride), Uridine 
diphosphate glucuronic acid (UDPGA; trisodium salt), valproic acid (VPA), ketamine (KTM) and 
cellulose dialysis membrane (molecular weight cutoff 12,000 Da) were purchased from Sigma 
Aldrich (Sydney, Australia). Fluconazole (FLZ) was a gift from Pfizer Australia (Sydney, 
Australia). Ketoconazole (KTZ) was a gift from Janssen research foundation. Baculovirus-
expressed UGT2B4, 2B7 and 2B15 enzymes were obtained from BD Gentest (Woburn, MA). 
Solvents and other reagents were of analytical reagent grade. 
 
2.2 Methods 
2.2.1 HLM and expression of recombinant UGT proteins 
Human livers (HL 7, 10, 12, 13 and 40) were obtained from the human liver 
‘bank’ of the Department of Clinical Pharmacology, Flinders Medical Centre. Approval was 
obtained from the Flinders Medical Centre Research Ethics Committee and from the donors’ 
next-of-kin for the procurement and use of human liver tissue in xenobiotic metabolism studies. 
Microsomes were prepared by differential centrifugation, as described by Bowalgaha et al. 
(2005). Microsomal protein concentrations were determined by the method of Lowry et al. (1951) 
using BSA as standard. Prior to use in incubations, HLM was activated by the addition of the 
pore-forming peptide alamethicin (50 μg/mg of protein) with preincubation on ice for 30 min 
(Boase and Miners, 2002).  
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UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 
2B17 cDNAs were stably expressed in a HEK293 cell line, as described previously (Sorich et al., 
2002; Stone et al., 2003; Uchaipichat et al., 2004). Cells were separately transfected with the 
individual UGT cDNAs cloned into the pEF-IRES-puro6 expression vector. Transfected cells 
were incubated in Dulbecco’s modified Eagle’s medium, which contained puromycin (1.5 mg/L), 
10% fetal calf serum and penicillin G sodium (100 U/mL)/streptomycin sulphate (100 μg/mL) in 
a humidified incubator with an atmosphere of 5% CO2, at 37°C. Following growth to at least 80% 
confluence, cells were harvested and washed with 0.1 M phosphate-buffered saline, pH 7.4. Cells 
were subsequently lysed by sonication using a sonicator (Heat Systems Ultrasonics, Plainsview, 
NY) set at microtip limit of 4, with four 1-s “bursts”, separated by 3 min with cooling on ice. 
Lysed samples were centrifuged at 12,000 ×g for 1 min at 4°C, and the supernatant fraction was 
removed and stored at -80°C until use. Given the relatively low activity of UGT2B4, 2B7 and 
2B15 expressed in HEK293 cells, Supersomes (BD Bioscience) expressing these enzymes were 
used in activity studies. The use of UGT2B enzymes from this source also allowed direct 
comparison of data from a previous study of COD glucuronidation (Court et al., 2003). 
Expression of each UGT was demonstrated by immunoblotting with a 
commercial UGT1A antibody (BD Bioscience) and a nonselective UGT antibody (raised against 
purified mouse Ugt) according to Uchaipichat et al. (2004) and an antibody that recognizes 
UGT2B7 and UGT2B10 (Kerdpin et al., 2009). In addition, activity measurements were 
performed with the recombinant proteins. Activities of recombinant UGT1A1, 1A3, 1A6, 1A7, 
1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17 were confirmed using the nonselective 4-MU 
according to a previously published procedure (Rowland et al., 2007). UGT1A4 activity was 
demonstrated using TFP as the substrate (Uchaipichat et al., 2006b), while UGT2B10 activity 
was confirmed by measurement of cotinine glucuronidation (Kerdpin et al., 2009). Furthermore, 
the effect of alamethicin on COD glucuronidation enzyme was investigated by baculovirus-
expressed UGT2B7 enzyme. 
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2.2.2 C6G glucuronidation assay  
Incubation mixtures, in a total volume of 200 μL, contained phosphate buffer 
(0.1 M, pH 7.4), MgCl2 (4 mM), UDPGA (5 mM), COD (0.025–10 mM) and activated HLM (1 
mg/mL) or baculovirus-expressed UGT2B4 and 2B7 enzymes (1 mg/mL). Following a 5 min pre-
incubation, reactions were initiated by the addition of UDPGA (5 mM) and performed at 37°C in 
a shaking water bath for 60 min (HLM) and 120 min (UGT2B4 and 2B7). Reactions were 
terminated by the addition of 2.5 μL of 70% v/v perchloric acid (HClO4) and cooling on ice for 
20 min. Samples were subsequently centrifuged at 5,000 ×g for 10 min at 10°C. A 120 μL aliquot 
of supernatant fraction was transferred to a 1.5-mL Eppendorf tube containing 2 μL of 4 M KOH, 
mixed, and centrifuged at 14,000 ×g for 5 min. Five microlitres of the supernatant fraction was 
injected directly into the HPLC column. For reactions carried out in the presence of BSA (2%), a 
lower range of COD concentration (0.025–3 mM) was employed as a consequence of the lower 
Km in the presence of albumin (see Results). Incubation conditions were as described for reactions 
in the absence of BSA. Due to the higher protein concentration, reactions were terminated by 
addition of 8 μl of 70% HClO4 and the supernatant fraction was treated with 6 μL of 4 M KOH. 
C6G formation was not detected when UDPGA was incubated with lysate from 
untransfected HEK293 cells or control Supersomes. Similarly, there was no evidence for the 
formation of a glucoside conjugate when lysate from untransfected HEK293 cells or control 
Supersomes was incubated with UDP-glucose. 
2.2.3 Quantification of C6G formation 
HPLC was performed using an Agilent 1100 series instrument (Agilent 
Technologies, Sydney, Australia) fitted with a Security Guard C18 cartridge (4 × 3 mm; 
Phenomenex, Sydney, Australia) and a Synergi Hydro-RP C18 column (3 × 150 mm; 4 μm 
Phenomenex, Torrance, CA). The mobile phase consisted of 2 mM triethylamine (TEA) (pH 
adjusted to 2.7 with HClO4) combined with 14% acetonitrile at a flow rate 1 mL/min. Column 
eluant was monitored by UV absorbance at 205 nm. Retention times of C6G and COD were 1.95 
and 3.08 min, respectively (Fig.2.1 and Fig.2.2). C6G formation in incubation samples was 
quantified by comparison of peak areas to those of a COD standard curve prepared in phosphate 
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buffer (0.1 M, pH 7.4) over the concentration range 2-40 μM. The slope of the COD standard 
curve was comparable to that generated with an authentic standard of C6G (Fig.2.3). Linearity of 
product formation with respect to incubation time and microsomal protein concentration was 
determined at substrate concentrations of 0.5 and 10 mM. The formation of C6G was linear with 
incubation times to at least 100 min and microsomal protein concentrations to at least 1.25 
mg/mL (Fig.2.4). Overall within day assay reproducibility was assessed by measuring C6G 
formation in 9 separate incubations of the same batch of pooled HLM. Coefficients of variation 
were 2.13% and 2.65% for the COD concentrations of 0.5 and 10 mM, respectively.  
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Figure 2.1 Representative HPLC chromatograms of codeine and codeine-6-glucuronide in 
human liver microsome: A) Codeine (5 mM) incubated with human liver microsomes (1 
mg/mL) for 60 min in the absence of UDPGA; B) Codeine (5 mM) incubated with human liver 
microsomes (1 mg/mL) for 60 min in the presence of UDPGA.  
A) 
B) COD 
COD 
C6G 
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Figure 2.2 Representative HPLC chromatograms of codeine and codeine-6-glucuronide in 
baculovirus-expressed UGT2B7 enzyme: A) Codeine (5 mM) incubated with baculovirus-
expressed UGT2B7 enzyme (1 mg/mL) for 120 min in the absence of UDPGA; B) Codeine (5 
mM) incubated with baculovirus-expressed UGT2B7 enzyme (1 mg/mL) for 120 min in the 
presence of UDPGA. 
A) 
B) 
COD 
COD 
C6G 
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Figure 2.3 Representative codeine and codeine-6-glucuronide standard curves: Panels A,C) 
Prepared in phosphate buffer (0.1 M, pH 7.4); Panels B,D) Prepared in phosphate buffer (0.1 M, 
pH 7.4) with pooled human liver microsomes (1 mg/mL) and 2% (w/v) bovine serum albumin. 
A) COD 
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Figure 2.4 Relationships between codeine-6-glucuronide formation by alamethicin-activated 
human liver microsomes: Panel A) Protein concentration curve of codeine (0.5 and 10 mM) 
incubated with protein 0.25-1.25 mg/mL for 60 min; Panel B) Incubation time curve of codeine 
(0.5 and 10 mM) incubated with protein 1 mg/mL for 20-100 min. 
A) 
B) 
COD 0.5 mM 
COD 10 mM 
COD 10 mM 
COD 0.5 mM 
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2.2.4 COD glucuronidation of recombinant UGT enzymes 
HEK293-expressed UGT enzymes (UGT 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 
1A10, 2B4, 2B7, 2B10, 2B15, and 2B17) activity screening studies were conducted at three COD 
concentrations (0.5, 2 and 10 mM), in the absence and presence 2% BSA, using the incubation 
and assay conditions described above. Due to the lower activity of recombinant UGT enzymes, 
the incubation mixture was modified by using 2 mg/mL for protein concentration and an 
incubation time of 120 min. 
2.2.5 COD and inhibitor binding to HLM and BSA 
The binding of COD and inhibitors (viz. KTM, KTZ and VPA) to HLM (1 
mg/mL) or a combination of HLM (1 mg/mL) and 2% BSA was investigated using the 
equilibrium dialysis method reported previously by McLure et al. (2000). One side of the dialysis 
cell contained the drug in phosphate buffer (0.1 M, pH 7.4), while the other compartment 
contained a suspension of either pooled HLM (1 mg/mL) or a combination of 2% BSA and HLM 
(1 mg/mL) in phosphate buffer (0.1 M, pH 7.4). Drug binding was characterized at 5 or 6 
concentrations over the ranges shown in Table 2.1: COD (25-10,000 μM); KTZ (2.5-250 μM); 
KTM (2-250 μM); and VPA (500-6,000 μM). The dialysis cell assembly was immersed in a 
water bath maintained at 37°C and rotated at 12 rpm for 4-5 hr. Control experiments were 
performed with phosphate buffer or HLM, or a combination of 2% BSA with HLM on both sides 
of the cell, at low and high drug concentrations, to ensure that equilibrium was attained. A 200 μL 
aliquot was collected from each cell and treated with 500 μL of ice-cold methanol containing 4% 
glacial acid, or 800 μL of ice-cold acetonitrile (for samples containing KTZ). Samples were 
chilled on ice for 20 min and subsequently centrifuged at 13,000 ×g for 5 min at 4°C. An aliquot 
of the supernatant fraction was analyzed by HPLC.  
The HPLC system employed was as described previously for the measurement 
of C6G formation. Chromatography conditions for each analyte are detailed in Table 2.1. HPLC 
chromatograms of COD, KTM, KTZ and VPA are illustrated in Fig.2.5, 2.6, 2.7, and 2.8, 
respectively. Drug concentrations of dialysis samples recovered from each side of the cell were 
calculated by reference to peak areas of standard curves that spanned both the bound and unbound 
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concentrations of each compound. Standard curves of each drug were prepared in phosphate 
buffer (0.1 M, pH 7.4) alone or in combination with phosphate buffer (0.1 M, pH 7.4) and protein 
(HLM and BSA), and then treated in the same manner as dialysis samples (Fig.2.9-2.12). Binding 
to incubation components, calculated as the drug concentration in the buffer compartment divided 
by the drug concentration in the protein compartment, is expressed as the fraction unbound in 
incubations (ƒu,inc). Microsomal and BSA binding data for FLZ have previously been reported by 
Uchaipichat et al. (2006a).  
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A) 
B) 
COD 
Figure 2.5 Representative HPLC chromatograms of codeine in equilibrium dialysis samples: A) 
Blank containing pooled human liver microsomes (1 mg/mL) in phosphate buffer (0.1 M, pH 
7.4); B) Codeine (0.1 mM) in pooled human liver microsomes (1 mg/mL) in phosphate buffer 
(0.1 M, pH 7.4). 
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A) 
B) 
KTM 
Figure 2.6 Representative HPLC chromatograms of ketamine in equilibrium dialysis samples: 
A) Blank containing pooled human liver microsomes (1 mg/mL) in phosphate buffer (0.1 M, pH 
7.4); B) Ketamine (10 μM) in pooled human liver microsomes (1 mg/mL) in phosphate buffer 
(0.1 M, pH 7.4). 
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A) 
B) 
KTZ 
Figure 2.7 Representative HPLC chromatograms of ketoconazole in equilibrium dialysis 
samples: A) Blank containing pooled human liver microsomes (1 mg/mL) in phosphate buffer 
(0.1 M, pH 7.4); B) Ketoconazole (10 μM) in a combination of 2% (w/v) bovine serum albumin 
with pooled human liver microsomes (1 mg/mL). 
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A) 
B) 
VPA 
Figure 2.8 Representative HPLC chromatograms of valproic acid in equilibrium dialysis 
samples: A) Blank containing pooled human liver microsomes (1 mg/mL) in phosphate buffer 
(0.1 M, pH 7.4); B) Valproic acid (1 mM) in pooled human liver microsomes (1 mg/mL) in 
phosphate buffer (0.1 M, pH 7.4). 
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Figure 2.9 Representative codeine standard curves for equilibrium dialysis samples: Panel A) 
Phosphate buffer (0.1 M, pH 7.4) alone; Panel B) Phosphate buffer (0.1 M, pH 7.4) with pooled 
human liver microsomes (1 mg/mL); Panel C) Phosphate buffer (0.1 M, pH 7.4) with pooled 
human liver microsomes (1 mg/mL) and 2% (w/v) bovine serum albumin. 
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Figure 2.10 Representative ketamine standard curves for equilibrium dialysis samples: Panel A) 
Phosphate buffer (0.1 M, pH 7.4) alone; Panel B) Phosphate buffer (0.1 M, pH 7.4) with pooled 
human liver microsomes (1 mg/mL); Panel C) Phosphate buffer (0.1 M, pH 7.4) with pooled 
human liver microsomes (1 mg/mL) and 2% (w/v) bovine serum albumin. 
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Figure 2.11 Representative ketoconazole standard curves for equilibrium dialysis samples: 
Panel A) Phosphate buffer (0.1 M, pH 7.4) alone; Panel B) Phosphate buffer (0.1 M, pH 7.4) 
with pooled human liver microsomes (1 mg/mL); Panel C) Phosphate buffer (0.1 M, pH 7.4) 
with pooled human liver microsomes (1 mg/mL) and 2% (w/v) bovine serum albumin. 
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Figure 2.12 Representative valproic acid standard curves for equilibrium dialysis samples: Panel 
A) Phosphate buffer (0.1 M, pH 7.4) alone; Panel B) Phosphate buffer (0.1 M, pH 7.4) with 
pooled human liver microsomes (1 mg/mL); Panel C) Phosphate buffer (0.1 M, pH 7.4) with 
pooled human liver microsomes (1 mg/mL) and 2% (w/v) bovine serum albumin. 
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Drug 
 
Concentration 
range 
Column Mobile phase Detector 
wavelength 
(nm) 
Flow rate 
(mL/min) 
Retention 
time 
(min) 
Calibration 
range 
Codeine 
 
 
No BSA: 
0.1-10 mM 
With BSA: 
0.25-3 mM 
 
Synergi Hydro-RP C18 
column (3 × 150 mm; 4 
μm) 
 
2 mM TEA (pH adjusted 
to 2.7 with HClO4) 
combined with 14% 
acetonitrile 
 
 
205 
 
 
1 
 
 
2.58 
 
 
0.1-6 mM 
Ketamine 
 
 
No BSA: 
10-250 μM 
With BSA: 
2-50 μM 
 
NovaPak C18 column 
(3.9 × 150 mm; 5 μm) 
 
 
50%:50% mixtures of 30 
mM phosphate buffer in 
TEA (pH 7.2) with 
acetonitrile 
 
 
215 
 
 
1 
 
 
2.48 
 
 
25-250 μM 
 
Ketoconazole 
 
 
No BSA: 
10-250 μM 
With BSA: 
10-250 μM 
 
NovaPak C18 column 
(3.9 × 150 mm; 5 μm) 
 
 
50%:50% mixtures of 30 
mM phosphate buffer in 
TEA (pH 7.2) with 
acetonitrile 
 
 
215 
 
 
1 
 
 
2.58 
 
 
20-250 μM 
Valproic acid 
 
 
No BSA: 
0.5-6 mM 
With BSA: 
0.5-6 mM 
 
Zorbax Eclipse XBD-C8 
analytical column 
(4.6 × 150 mm; 5 μm) 
 
55%:45% mixture of 
phosphate buffer (pH 3.1, 
25 mM) with acetonitrile 
 
 
210 
 
 
1 
 
 
6.12 
 
 
0.5-5 mM 
Table 2.1 HPLC conditions for the measurement of drug binding by equilibrium dialysis. 
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2.2.6 Inhibition of COD glucuronidation by inhibitors  
Pooled HLM was prepared by mixing equal protein amounts from the five livers 
(H7, H10, H12, H13, and H40) used in the kinetic studies. The IC50 values for inhibition of COD 
glucuronidation were determined using the COD concentration corresponding to the apparent Km 
value obtained from the kinetic studies of COD glucuronidation by HLM (i.e. 2 and 0.3 mM) in 
the absence and presence of BSA (2%), respectively. C6G activity was measured at five inhibitor 
concentrations ranging from 0.05-2.5 mM (FLZ); 0.05-1 mM (KTM); 0.05-1 mM (KTZ); and 1-
20 mM (VPA) in the absence of BSA. In the presence of BSA, inhibitor concentrations were in 
the same range as those in the experiments without BSA except that the concentration range was 
1-20 μM and 0.5-10 mM for KTM and VPA, respectively.  
To determine the Ki value and inhibition mechanisms, four inhibitor 
concentrations in the range of 0.1-2.5 mM (FLZ); 25-250 μM (KTM); and 20-250 μM (KTZ) 
were used at each of three COD concentrations (1, 2, and 4 mM) in the absence of BSA. For 
incubations in the presence of BSA, the KTZ concentration range was similar to that in the 
absence of BSA, but the FLZ and KTM concentrations ranges were 0.05-1 mM and 2-20 μM, 
respectively and the three COD concentrations used were 0.15, 0.3, and 0.6 mM. FLZ and KTM 
were dissolved in water while KTZ and VPA were dissolved in methanol such that the final 
concentration of methanol added to incubations was 1% v/v which had a negligible effect on 
HLM (Uchaipichat et al., 2004). Where the binding was measurable, the concentration of each 
inhibitor was corrected by the ƒu,inc  value to determine the IC50 and Ki values. 
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2.2.7 Data analysis 
2.2.7.1 COD kinetic parameters 
The kinetic data were presented as mean (±SD.) values derived from the 
experimental data. Kinetic constants for COD glucuronidation by HLM determined in the 
presence and absence of BSA were generated by fitting untransformed experimental data to the 
following equations.  
The Michaelis–Menten equation (equation 2.1; Houston and Kenworthy, 2000): 
 
 
where υ is the rate of reaction, Vmax is the maximum velocity, Km is the 
Michaelis-Menten constant (substrate concentration at 0.5 Vmax) and [S] is the substrate 
concentration. 
The substrate inhibition equation (equation 2.2; Houston and Kenworthy, 2000):  
 
 
where Ksi is the constant describing the substrate inhibition interaction. 
The Hill equation which describes sigmoidal kinetics (equation 2.3; Houston and 
Kenworthy, 2000): 
 
 
where the substrate concentration resulting in 50% of Vmax (S50) is analogous to 
Km in the Michaelis-Menten equation, and n is the Hill coefficient. 
In all cases, fitting was based on unbound substrate concentrations in incubations 
and performed with EnzFitter (Biosoft, Cambridge, UK). The CLint for COD glucuronidation by 
HLM and recombinant UGT2B7 was determined as Vmax/Km in the case of Michaelis-Menten and 
substrate inhibition kinetics. For sigmoidal kinetic, the CLmax provides an estimate of the highest 
clearance attained, which is when the enzyme is fully activated before saturation occurs. The 
CLmax was determined as a following equation (Houston and Kenworthy, 2000). 
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where Vmax is the maximum velocity, S50 is the substrate concentration resulting 
in 50% of Vmax, and n is the Hill coefficient.  
The concentration of the inhibitor that is required to produce the IC50 was 
determined by using EnzFitter (Biosoft). The Ki value for determination the effect of each 
inhibitor on COD glucuronidation was determined by fitting the expressions for competitive, 
noncompetitive, and mixed inhibition to experimental data using EnzFitter (Biosoft). Goodness of 
fit to kinetic and inhibition mechanisms were assessed from the F statistic, r2 values, parameter 
standard error (SE.) estimates and 95% confidence intervals. Kinetic constants are reported as the 
value ± SE. of the estimated parameters.  
2.2.7.2 IV-IVE  
A-1) Prediction of COD glucuronidation clearance 
 Microsomal COD glucuronidation intrinsic clearance by HLM is determined as 
units of μl/min/mg microsomal protein and subsequently converted to whole-liver CLint (CLint.liver) 
using scaling factors that correct for microsomal yield and liver weight according to the following 
equation:  
 
 
where MPPGL is the mass of microsomes per gram of human liver tissue taken 
as 38 mg/g corresponding to the geometric mean of the microsomal yield reported by Hakooz et 
al. (2006) and LW is the average weight of a huam liver (1,500 g). The result was multiplied by 
0.00006 to express CLint in L/hr. In vivo CLH was predicted using the expression for the well-
stirred model (Houston, 1994):  
 
 
where ƒu is fraction unbound in blood and QH is liver blood flow, assumed to be 
90 L/hr. The fraction of drug unbound in blood was calculated as ƒu = ƒu,p /RB, where RB is the 
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blood to plasma concentration ratio and ƒu,p is the fraction unbound in plasma. For COD, ƒu,p was 
taken as 0.93 (Soars et al., 2002) and RB as 1 (Carlile et al., 1999).  
The In vivo CLH value for COD glucuronidation was obtained from the 
literature. The mean COD systemic clearance is 44.95 L/hr per 70 kg (Bertz and Granneman, 
1997; Vozeh, 1988). Because approximately 80% of COD was glucuronidated to C6G (Yue et al., 
1991), therefore the plasma COD clearance by glucuronidation in vivo was taken as 35.96 L/hr 
per 70 kg.  
A-2) Prediction of the inhibition of COD hepatic clearance 
The extent of inhibition of COD hepatic clearance (determined as the ratio of the 
areas under the plasma COD concentration - time curves with and without inhibitor co-
administration) was predicted using the equation for oral administration of an hepatically cleared 
drug (Miners et al., 2010);  
 
 
 
where [I] is the inhibitor concentration at the enzyme active site; ƒm is the 
fraction of COD hepatic clearance via glucuronidation (taken here as 80%; Yue et al., 1991), and 
Ki is the inhibitor constant generated in vitro in the presence of BSA. The [I] value was taken as 
the maximum hepatic inlet concentration of the drug in vivo (Miners et al., 2010); 
 
 
where [Imax], ka, Fa, and QH are the maximum total drug concentration in the 
systemic circulation associated with a given dose (Table 2.2), absorption rate constant, and 
fraction absorbed from the GI tract, and liver blood flow (taken as 90 L/hr or 1.5 L/min), 
respectively. The hepatic maximum unbound inlet concentration was calculated as the product of 
[Iinlet,max] and fraction unbound in plasma. Maximum hepatic inlet concentrations (total and 
unbound) were calculated from published pharmacokinetic data for FLZ (Sahai et al., 1994; 
Uchaipichat et al., 2006a). In contrast to FLZ, since KTM is administrated in favor of the IV route 
and there are no reliable estimates of ka and Fa for KTZ, it was not possible to calculate Iinlet,max. 
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Thus, IV-IVE was based on reported the maximum concentration in plasma both total and 
unbound inhibitor concentrations for KTM (Clements ans Nimmo, 1981), and KTZ (Badcock et 
al., 1987; Daneshmend and Warnock, 1988). 
 
Table 2.2 Pharmacokinetic parameters for the calculation the extent of inhibition of COD 
hepatic clearance based on the AUC ratio. 
Inhibitors Parameters 
Fluconazole Ketamine Ketoconazolea 
Route of administration 
Molecular weight (g/mol) 
Dose (mg/day) 
Dose (μM) 
Plasma protein binding (%) 
ƒu,p 
Fa 
Ka (min-1) 
Imax (μM) 
Ki (μM) 
PO 
306.27 
400 
1306 
11 
0.89 
1 
0.1 
77.70 
202 
IV 
237.73 
18.70 
78.66 
47 
0.53 
- 
- 
0.45 
3.51 
- 
531.43 
200 
376.34 
99 
0.01 
- 
- 
3.20 
0.66 
  a Calculation was based on reported the maximum concentration in plasma. 
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CHAPTER 3 
RESULTS 
3.1 Binding of COD and inhibitors to HLM and BSA 
Nonspecific binding to HLM and binding to HLM plus BSA was characterized 
here for COD and the putative inhibitors KTZ, KTM and VPA (Table 3.1). Previous studies from 
this laboratory demonstrated that FLZ does not bind nonspecifically to HLM, and that binding of 
FLZ to HLM plus 2 % BSA is negligible (Uchaipichat et al., 2006a). The binding of COD and 
VPA to HLM alone was negligible across the concentration ranges investigated. The binding of 
COD to the mixture of HLM and BSA (2%) was also minor. KTM bound modestly to HLM plus 
BSA, although the binding of KTM to HLM alone was negligible. KTZ bound extensively to both 
HLM and to HLM plus BSA, with mean ƒu,inc  values of 0.27 ± 0.01 and 0.09 ± 0.01, respectively. 
Consistent with a previous report (Rowland et al., 2006), the binding of VPA to the HLM/BSA 
mixture was concentration dependent; ƒu,inc values ranged from 0.29 at the lowest VPA 
concentration (0.5 mM) to 0.77 at the highest concentration (6 mM). Where observed, binding of 
inhibitors to HLM and to HLM plus BSA was accounted for in the calculation of IC50 and Ki 
values.  
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Table 3.1 Binding of codeine and inhibitors to human liver microsome (1 mg/ml) in the absence 
and presence of bovine serum albumin. 
       Results are presented as fraction unbound (ƒu,inc ) ± SD. 
    a Data taken from Uchaipichat et al., 2006a. 
      bƒu,inc  concentration dependent in the range 0.5-6 mM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fraction unbound in incubations (ƒu,inc ) Drugs 
HLM HLM plus 2% BSA 
Codeine 0.98 ± 0.013 0.96 ± 0.007 
Fluconazolea 1.04 ± 0.020 0.92 ± 0.027 
Ketamine 
Ketoconazole 
0.98 ± 0.019 
0.27 ± 0.005 
0.79 ± 0.020 
0.09 ± 0.003 
Valproic acid 0.99 ± 0.007 0.29-0.77b 
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3.2 C6G glucuronidation by HLM 
Representative kinetic plots for C6G formation by HLM in the absence and 
presence of 2% BSA are shown in Fig.3.1, and derived kinetic constants are given in Table 3.2. 
C6G formation by HLM in the absence of BSA was well described by the Michaelis-Menten 
equation, whereas weak substrate inhibition (Ksi approximately 40-times higher than Km) was 
apparent for kinetic studies performed in the presence of BSA (2%). A transition from Michaelis 
Menten to weak substrate inhibition kinetics in the presence of BSA has been observed previously 
for AZT (Uchaipichat et al., 2006a), another UGT2B7 substrate. The addition of BSA to 
incubations resulted in an 8-fold reduction in Km without an effect on Vmax (Table 3.2). 
Microsomal CLint increased in proportion to the change in Km. Kinetic constants for COD 
glucuronidation by pooled HLM, prepared by mixing equal protein amounts of microsomes from 
the 5 separate livers, were similar to the mean data shown in Table 3.2; Km and Vmax values in the 
absence of BSA were 2.15 mM and 584 pmol/min.mg, while Km, Ksi and Vmax values obtained for 
incubations supplemented with BSA (2%) were 0.23 mM, 8.15 mM, and 436 pmol/min.mg, 
respectively. 
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Figure 3.1 Kinetic plots for codeine 6-glucuronidation by microsomes from a representative 
human liver (HL13) and pooled human livers generated in the absence and presence of bovine 
serum albumin: Panels A and C) plots of the rate of product (C6G) formation versus substrate 
concentration; Panels B and D) Eadie-Hofstee plots. Points are experimentally derived values 
while curves are from model fitting. 
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Table 3.2 Derived kinetic parameters for codeine glucuronidation by human liver microsome determined in the absence and presence of bovine serum. 
 
 
 
 
 
 
 
 
                      
 
 
 
 
  Data presented as mean ± SE. of parameter fit. 
                              a Kinetic constants derived from fitting with the Michaelis-Menten equation. 
                              b Kinetic constants derived from fitting with the substrate inhibition equation. 
                              c CLint calculated as Vmax/Km for both Michaelis-Menten and substrate inhibition kinetics. 
 Without BSAa  With 2% BSAb 
 Km 
(mM) 
Vmax 
(pmol/min.mg) 
CLintc 
( μl/min/mg) 
 Km 
(mM) 
Vmax 
(pmol/min.mg) 
Ksi 
(mM) 
CLintc 
(μL/min/mg) 
HL7 2.35 ± 0.01 440 ± 1.2 0.19  0.32 ± 0.01 430 ± 9.7 8.20 ± 1.04 1.34 
HL10 2.68 ± 0.02 312 ± 0.9 0.12  0.34 ± 0.01 303 ± 6.2 9.49 ± 1.19 0.89 
HL12 3.13 ± 0.18 920 ± 20.8 0.29  0.28 ± 0.02 848 ± 23.8 14.42 ± 2.78 3.03 
HL13 2.29 ± 0.12 754 ± 13.2 0.33  0.26 ± 0.001 680 ± 0.7 10.63 ± 0.12 2.62 
HL40 1.16 ± 0.01 438 ± 0.5 0.38  0.24 ± 0.01 447 ± 6.6 14.46 ± 1.50 1.86 
Mean ± SD. 2.32 ± 0.73 573 ± 253 0.26 ± 0.11  0.29 ± 0.04 541 ± 218 11.44 ± 2.87 1.95 ± 0.88 
Pooled HLM 2.15 ± 0.13 584 ± 16 0.27  0.23 ± 0.01 436 ± 12 8.15 ± 1.03 1.90 
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3.3 COD glucuronidation by recombinant UGTs 
UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 
2B17 separately expressed in an HEK293 cell line were screened for C6G formation at three 
COD concentrations (0.5, 2, and 10 mM), both in the absence and presence BSA (2%). Although 
expression of all UGT enzymes was demonstrated by immunoblotting and activity measurements 
(data not shown), only UGT2B4 and UGT2B7 catalyzed the 6-glucuronidation of COD (Fig. 3.2). 
However, rates of C6G formation by these enzymes expressed in HEK293 cells were relatively 
low. Rates of COD glucuronidation by UGT2B4 at 10 mM was 2.1 pmol/min.mg in the absence 
of BSA and 1.7 and 1.3 pmol/min.mg at 2 and 10 mM COD concentrations in the presence of 
BSA, respectively. Respective rates of COD glucuronidation by UGT2B7 at COD concentrations 
of 0.5, 2 and 10 mM were 1.2, 2.8 and 4.2 pmol/min.mg in the absence of BSA, and 2.5, 3.1 and 
4.6 pmol/min.mg in the presence of BSA. Compared to HEK293-expression, baculovius mediated 
expression in Sf9 cells UGTs showed higher UGT2B4 and UGT2B7 activities. Respective rates 
of C6G formation by baculovirus-expressed UGT2B4 at COD concentrations of 0.5, 2 and 10 
mM were 6, 34 and 59 pmol/min.mg in the absence of BSA, and 23, 37 and 39 pmol/min.mg in 
the presence of BSA. With Sf9-expressed UGT2B7, respective rates of C6G formation at COD 
concentrations of 0.5, 2 and 10 mM were 13, 33 and 39 pmol/min.mg in the absence of BSA, and 
36, 46 and 48 pmol/min.mg in the presence of BSA.  
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Figure 3.2 Representative the codeine glucuronidation by recombinant UGTs in HEK293-
expression: Panel A) in the absence and Panel B) the presence bovine serum albumin. Codeine 
concentration; 0.5 mM (    ), 2 mM (    ), and 10 mM (    ).  
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3.4 COD glucuronidation by recombinant UGT2B4 and UGT2B7  
In contrast to HLM, COD glucuronidation by baculovius-expressed UGT2B4 
and UGT2B7 exhibited sigmoidal kinetics (Fig.3.3), which were modeled using the Hill equation. 
Addition of BSA to incubations resulted in approximate 8- and 4- fold reductions in the respective 
S50 values for UGT2B4 and  UGT2B7 (Table 3.3). While the addition of BSA had no effect on 
the Vmax and Hill coefficient for UGT2B7 catalyzed COD glucuronidation, the Vmax and Hill 
coefficient obtained for UGT2B4 in the presence of BSA were decreased and increased, 
respectively, compared to experiments performed in the absence of albumin (Table 3.3).  
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Figure 3.3 Kinetic plots for codeine 6-glucuronidation by baculovius-expressed UGT2B7 and 
UGT2B4 generated in the presence and absence of bovine serum albumin: Panels A and C) plots 
of the rate of product (C6G) formation versus substrate concentration; Panels B and D) Eadie-
Hofstee plots. Points are experimentally derived values while curves are from model fitting. 
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Table 3.3 Derived kinetic parameters for codeine glucuronidation by baculovius-expressed UGT2B4 and UGT2B7 determined in the absence and presence 
of bovine serum albumin. 
 
Data presented as mean ± SE. of parameter fit. 
Kinetic constants derived from fitting with the Hill equation. 
 
 
 
 Without BSA  With 2% BSA 
 S50 
(mM) 
Vmax 
(pmol/min.mg) 
n CLmaxa 
( μL/min/mg) 
 S50 
(mM) 
Vmax 
(pmol/min.mg) 
n CLmaxa 
( μL/min/mg) 
UGT2B4 2.61 ± 0.001 79 ± 0.02 1.19 ± 0.001 0.02  0.32 ± 0.004 37 ± 0.16 1.50 ± 0.03 0.06 
UGT2B7 1.07 ± 0.03 49 ± 0.63 1.17 ± 0.02 0.03  0.27 ± 0.01 53 ± 0.44 1.22 ± 0.03 0.12 
a CLmax calculated as 1/n
50
max
1)n(n
1)(n
S
V
−
−×  
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3.5 Inhibition of human liver microsomal COD glucuronidation 
 Experiments conducted to calculate IC50 and Ki values employed pooled HLM 
as the enzyme source, with and without 2% BSA. The effects of four concentrations of each 
putative inhibitor were assessed initially at the COD concentrations corresponding to the 
approximate mean Km values for C6G formation in the absence (2 mM) and presence (0.3 mM) of 
2% BSA (Table 3.4). Inhibitor binding to HLM and BSA was accounted for in the calculation of 
inhibition parameters (IC50 and Ki). FLZ and VPA were weak to moderate inhibitors of COD 
glucuronidation, with estimated IC50 values > 2 mM in the absence of BSA (Table 3.4). Potent 
inhibition was observed for KTM and KTZ, with IC50 values ranging from 4.5 to 70 μM. Addition 
of BSA (2%) to incubations typically resulted in an 8- to 12- fold reduction in the IC50 (Table 
3.4). Based on data from the above inhibition screening studies, kinetic experiments were 
performed to determine Ki values for FLZ, KTM, and KTZ. Results are shown in Fig.3.4 as 
Dixon plots. Inhibition data for FLZ, KTM, and KTZ were well modeled using the expression for 
competitive inhibition of human liver microsomal COD glucuronidation. Consistent with the IC50 
data, Ki values generated in the presence of BSA were lower (approximately 6- to 17- fold) 
compared to Ki obtained in the absence of albumin and potent inhibition of C6G formation was 
observed for KTM and KTZ (Table 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
  
105 
 
 
Table 3.4 IC50 values for inhibition of human liver microsomal codeine glucuronidation 
determined in the absence and presence of bovine serum albumin. 
Data given as IC50 ± SE. of parameter fit.  
Concentration range of each inhibitor was shown in parenthesis. 
a IC50 value is the unbound concentration in the incubation medium (i.e. corrected for binding to 
HLM and BSA). 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitors  IC50 (μM) 
  Without BSA  With 2%BSA 
Fluconazole  2970 ± 16 
(50-2500 μM) 
 371 ± 0.60a 
(46-2300 μM)a 
Ketamine  70.1 ± 3.88 
(50-1000 μM) 
 5.9 ± 0.31a 
(1.6-15.8 μM)a 
Ketoconazole  17.2 ± 0.11a 
(4.5-270 μM)a 
 2.0 ± 0.03a 
(1.5-90 μM)a 
Valproic acid  4604 ± 509 
(1-20 mM) 
 580 ± 1.78a 
(0.15-8.6 mM)a 
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Figure 3.4 Dixon plots for fluconazole, ketamine, and ketoconazole inhibition of codeine 6-
glucuronidation by pooled human liver microsomes generated in the absence (panels A, C, and 
E) and presence (panels B, D, and F) of bovine serum albumin. Inhibitor concentrations are 
corrected for binding to human liver microsomes and bovine serum albumin (i.e. unbound 
concentration in the incubation medium). 
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Table 3.5 Ki values for the inhibition of human liver microsomal codeine glucuronidation 
determined in the absence and presence of bovine serum albumin. 
      Ki ± SE. of parameter fit.  
     Data were best fitted with the expression for competitive inhibition. 
       a Ki value based on the unbound concentration in the incubation medium (i.e. corrected for 
binding to HLM and BSA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitors  Ki (μM) 
  Without BSA  With 2%BSA 
Fluconazole  1341 ± 0.04  202 ± 0.001a 
Ketamine  52 ± 0.75  3.51 ± 0.09a 
Ketoconazole  11.3 ± 1.5a  0.66 ± 0.01a 
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3.6 Effect of VPA on COD glucuronidation in HLM 
The effects of VPA on the kinetics of COD glucuronidation are presented in 
Fig.3.5 and Table 3.6. The effect of VPA on COD glucuronidation was investigated in pooled 
HLM over the COD concentration range 0.25-5 mM. In the absence of BSA (2%), COD 
glucuronidation by HLM was best modeled with the Michaelis-Menten equation, whereas kinetic 
data were consistent with weak substrate inhibition for incubations performed in the presence of 
BSA. In both the absence and presence of BSA, addition of VPA changed the kinetics of C6G 
formation to sigmoidal. The sigmoidal kinetics were best fitted with the Hill equation. The Km (or 
S50) values for COD glucuronidation were increased 4.8- to 7.7-fold with increasing VPA 
concentration. The Km (or S50) values increased from 2.04 mM (no VPA) to 9.82 mM (at the 
highest concentration of VPA, 6 mM), and from 0.18 mM (no VPA) to 1.39 mM (at the highest 
unbound concentrations of VPA of 2.14 mM) in the absence and presence of BSA, respectively. 
However, Vmax values and the Hill coefficient for COD glucuronidation were essentially 
unchanged by VPA. 
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Figure 3.5 Kinetic plots of codeine 6-glucuronidation by pooled human liver microsomes in the 
presence of increasing valproic acid concentration in the absence (Panel A and B) and presence 
(Panel C and D) of bovine serum albumin. Panel A and C, plots of the rate of product (C6G) 
formation versus substrate concentration; panel B and D, and Eadie–Hofstee plots.  
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Table 3.6 Derived kinetic parameters for codeine glucuronidation with increasing concentrations of valproic acid in the absence and presence of bovine 
serum albumin. 
a Data presented as mean ± SE. of parameter fit;b Michaelis-Menten equation (MM); c Hill equation (Hill); d Substrate inhibition (SI) with Ksi = 23.56 ± 2.36 
mM; S50: Substrate concentration resulting in 50% of Vmax; Km: Michaelis-Menten constant; Vmax: Maximum of velocity; Ksi: Constant describing the 
substrate inhibition interaction; n: Hill coefficient. 
  Without BSAa  With 2% BSAa 
[VPA] 
mM 
Kinetic 
equations 
 
Km or S50 
(mM) 
Vmax 
(pmol/min.mg) 
n 
 
[Unbound 
VPA] 
mM 
Kinetic 
equations 
Km or S50 
(mM) 
Vmax 
(pmol/min.mg) 
n 
 
0 mMb MM 2.04 ± 0.004 482 ± 0.37 - 0 mMd SI 0.18 ± 0.01 319 ± 5.20 - 
1 mMb MM 4.17 ± 0.003 532 ± 0.22 - 0.13 mMc Hill 0.36 ± 0.01 266 ± 2.52 1.50 ± 0.07 
2 mMc Hill 3.48 ± 0.03 356 ± 1.66 1.25 ± 0.02 0.44 mMc Hill 0.44 ± 0.02 270 ± 3.81 1.39 ± 0.08 
4 mMc Hill 6.50 ± 0.53 435 ± 19.38 1.15 ± 0.03 0.59 mMc Hill 0.63 ± 0.02 262 ± 3.46 1.30 ± 0.06 
5 mMc Hill 5.94 ± 0.40 361 ± 19.38 1.19 ± 0.03 1.15 mMc Hill 1.02 ± 0.03 255 ± 2.97 1.26 ± 0.04 
6 mMc Hill 9.82 ± 0.65 446 ± 17.34 1.13 ± 0.02 2.14 mMc Hill 1.39 ± 0.01 256 ± 0.92 1.18 ± 0.01 
  
111 
3.7 Effect of alamethicin on COD glucuronidation by baculovirus-expressed 
UGT2B7 enzyme 
 
  The effect of alamethicin on C6G formation was investigated in the absence of 
BSA (2%) by baculovirus-expressed UGT2B7 enzyme (Fig.3.6). In the absence of alamethicin, 
COD glucuronidation was fitted with Sigmoidal kinetic with Vmax = 46.43 ± 0.43 pmol/min/mg, 
S50 = 1.09 ± 0.02 mM, and Hill coefficient (n) = 1.22 ± 0.02. Although the rate of C6G formation 
was changed to the generic two-site model for incubation pre-incubated with alamethicin, effect 
on Vmax (37.30 ± 1.17 pmol/min/mg) and Ks (1.26 ± 0.41 mM) values were not observed when 
compared with the rates measured in the absence of alamethicin. 
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Figure 3.6 Kinetic plots for codeine 6-glucuronidation in the absence of bovine serum albumin 
by baculovius-expressed UGT2B7 generated in the absence and presence of alamethicin: Panels 
A) plots of the rate of product (C6G) formation versus substrate concentration; Panels B) Eadie-
Hofstee plots. Points are experimentally derived values while curves are from model fitting. 
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3.8 Prediction of COD glucuronidation clearance 
For IV-IVE of the COD glucuronidation kinetic data, in vitro CLint values 
obtained from hepatic microsomes were extrapolated to in vivo blood CLH values using the well-
stirred model as described in data analysis. In the absence of BSA, the mean (±SD.) predicted 
CLH value for COD elimination via glucuronidation was 0.82 ± 0.34 L/hr. This was increased 7-
fold, to 5.82 ± 2.72 L/hr, in the presence of BSA. As above mentioned in data analysis, the mean 
observed in vivo CLH value is 35.9 L/hr. Therefore, the predicted CLH value in the absence of 
BSA was lower than the known CLH value (by 44-fold). Addition of BSA (2%) improved the 
prediction of CLH, but this parameter was still underestimated by approximately 6-fold. The 
derived kinetic parameters by IV-IVE were shown in Table 3.7.  
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Table 3.7 Derived kinetic parameters of prediction of codeine glucuronidation clearance in the 
absence and presence of bovine serum albumin. 
Parameters Without BSA  With 2% BSA 
Mean CLint 
(μl/min/mg) 
0.26 ± 0.11 
  
1.95 ± 0.88 
 
Mean CLint.liver 
(ml/min/kg) 
0.89 ± 0.37 
  
6.66 ± 3.01 
 
Mean CLH 
(L/hr) 
0.82 ± 0.34 
  
5.80 ± 2.72 
 
Fold 
of underestimationa 
44  6 
Data were presented as mean ± SD. 
a Predicted CLH value by IV-IVE compared to the observed in vivo CLH value (35.9 L/hr). 
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3.9 Prediction of inhibition of COD hepatic clearance 
Predicted changes in the AUC for COD when coadministered with FLZ and 
KTZ are given in Table 3.8. Based on total inhibitor concentration in blood for the doses 
indicated in Table 3.8, predicted AUC ratios were increased 1.10-, 1.60-, and 2.97-fold with 
KTM, FLZ and KTZ, respectively. When considered in terms of unbound inhibitor concentration 
in blood, no interaction was predicted with KTM and KTZ. The predicted change in the AUC 
ratio based on unbound FLZ concentration did not change appreciably given the minor plasma 
protein binding of this compound.   
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Table 3.8 Predicted increase in the area under the codeine plasma concentration-time from co-
administration of fluconazole, ketamine, and ketoconazole. 
a Dose calculated as free base where drug administered as a salt. 
b Hepatic maximum input concentration, except for KTM and KTZ (maximum plasma 
concentration; see Methods). 
c Sahai et al. (1994). 
d Clements and Nimmo (1981). 
e Badcock et al. (1987). 
 
 
 
 
 
 
 
 
 
Predicted fold increase in AUC ratio based on: 
Drugs (in vitro dose)a Total inhibitor concentrationb  Unbound inhibitor 
concentrationb 
Fluconazole 
(400 mg/dayc) 
Ketamine 
(18.7 mg/dayd) 
Ketoconazole 
(200 mg/daye) 
1.60 
 
1.10 
 
2.97 
 
 1.54 
 
1.05 
 
1.04 
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CHAPTER 4 
DISCUSSIONS 
COD is an opioid drug used to treat mild to moderate pain. COD exerts its 
therapeutic effects through the formation of morphine. Approximately 5-10% of the COD dose is 
converted to morphine by CYP2D6 catalysed O-demethylation. The major metabolic pathway of 
COD is the formation of C6G (Yue et al., 1991). 
Initial studies aimed to characterize the effect of BSA on COD glucuronidation 
by HLM and confirm the contributions of UGT2B4 and UGT2B7 to C6G formation. C6G 
formation in the absence of BSA exhibited Michaelis-Menten kinetics. Kinetic constants derived 
here in the absence of BSA were similar to those reported previously by Court et al. (2003). 
Addition of BSA (2%) to incubations resulted in an 8-fold reduction in Km without an effect on 
Vmax. A similar affect has been reported for the glucuronidation of AZT by HLM, where the Km 
value was decreased by approximately 10 to 13-fold. Consequently, there was a 10 to 15-fold 
increase in CLint (Uchaipichat et al., 2006b; Rowland et al., 2007). An increase in microsomal 
CLint (2 to 13-fold) of other UGT2B7 substrates (viz. diclofenac, gemfibrozil, ketoprofen, and 
naloxone) has also recently been observed in the presence of BSA (Kilford et al., 2009). These 
data confirm that Km or microsomal CLint values for UGT2B7 substrates are typically 
overestimated by approximately an order of magnitude when HLM are used as the enzyme source 
in the absence of albumin supplementation. The mechanism of the albumin on improving the 
kinetic parameter with a reduction in the “apparent” Km has been proposed recently. It involved 
sequestration of long-chain unsaturated fatty acids (arachidonic, linoleic, oleic) released from the 
microsomal membrane during the course of an incubation and acted as potent competitive 
inhibitors of UGT2B7 (Rowland et al., 2007, 2008a,b). The screening of 13 recombinant UGT 
enzymes expressed in HEK293 cell demonstrated that only UGT2B4 and UGT2B7 contributed 
the C6G formation. This result was also consistent with previous published data that investigated 
in baculovirus-expressed UGT enzymes (Court et al., 2003). However the rates of C6G formation 
in HEK293-expression were approximately 10-fold lower than in baculovirus-expression. 
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Although it is acknowledged that UGT expression may differ from enzyme to enzyme and 
between expression systems, the use of positive controls precluded absent activity as a reason for 
the inability of UGTs other than 2B4 and 2B7 to form C6G. 
 In contrast to the Michaelis-Menten (or weak substrate inhibition) kinetics 
observed for C6G formation by HLM, COD glucuronidation by UGT2B4 and UGT2B7 exhibited 
sigmoidal kinetics. Differences in kinetic behavior between HLM and recombinant UGTs have 
been observed in other studies. Naproxen acyl glucuronidation by HLM exhibited biphasic 
kinetics. In contrast, the conversion of naproxen to naproxen acyl glucuronide was best described 
by the Michaelis-Menten equation for UGT1A3, UGT1A6, and UGT2B7, the Hill equation with 
negative cooperativity for UGT1A9, and the substrate inhibition equation for UGT1A10. 
Similarly, desmethylnaproxen phenolic glucuronidation by HLM showed apparent biphasic 
kinetics, while negative cooperative and Michaelis–Menten kinetics were observed with UGT1A9 
and UGT1A10, respectively (Bowalgaha et al., 2005). Reasons for the inter-system differences 
remain unknown, but may reflect membrane effects on protein function (Miners et al., 2006). The 
difference in the kinetic model (sigmoidal versus hyperbolic) between present and previously 
(Court et al., 2003) reported data for UGT2B7 may arise from our use of more points at lower 
substrate concentrations, which favors detection of sigmoidal kinetics.  
In addition, to confirm the effect of alamethicin on different enzyme sources, 
preincubation of Supersomes expressing UGT2B7 was investigated. The result showed that 
alamethicin has no effect on COD glucuronidation, both in the absence and presence of BSA 
(data not shown). Kaivosaari et al. (2008) have similarly demonstrated that alamethicin is without 
affect on the activity of UGT1A4 expressed in baculovirus infected insect cells. In contrast to 
recombinant UGT2B7 expressed in insect cells, pretreatment of HLM with alamethicin results in 
a 2 to 3-fold increase in microsomal UGT2B7 activity, as evidenced here by effects on C6G 
formation and in previous studies with AZT, morphine, diclofenac, gemfibrozil, ketoprofen, and 
naloxone  (Fisher et al., 2000; Boase and Miners, 2002; Kilford et al., 2009). Similarly, the rates 
of glucuronidation of estradiol and acetaminophen which are relatively selective probes for 
human UGT1A1 and UGT1A6 were increased by approximately 2- to 3-fold with alamethicin-
treated microsomes (Fisher et al., 2000). These results demonstrate that the alamethicin appears to 
increase human liver microsomal UGT enzyme activity in a substrate-independent fashion, 
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presumably by facilitating entry of substrate and UDPGA into, and the diffusion of conjugate and 
UDP out of, the lumen of the ER (Fisher et al., 2000). 
S50 values for COD glucuronidation by both UGT2B4 and UGT2B7 were 
reduced by BSA, and the S50 values generated in the presence of BSA were close in value. 
However, in contrast to HLM and UGT2B7, the Vmax for UGT2B4 was also reduced by BSA. In 
general, identification of the UGT enzyme responsible for the glucuronidation of a compound in 
vitro referred to as “reaction phenotyping” may be underpinned by several approaches: (1) a 
reduction in glucuronidation of the test compound by individual UGT-enzyme–selective 
inhibitors; (2) screening for glucuronidation by a battery of recombinant UGTs, together with 
comparison of Km values for glucuronidation by the recombinant enzyme and HLM; (3) 
competitive inhibition of the glucuronidation of a UGT-enzyme–selective substrate by the test 
compound, with Ki matching Km; and (4) a significant correlation between the rates of 
glucuronidation of the test compound and a UGT-enzyme–selective substrate in microsomes  
from a panel of livers (Miners et al., 2006, 2010). 
Although, this study indicated that the UGT2B4 and UGT2B7 contribute the 
C6G formation, a significant enzyme between UGT2B4 and UGT2B7 is not unclear. While it is 
not possible to determine the relative contribution of UGT enzymes to a metabolic pathway in the 
absence of relative protein expression data, it is noteworthy that UGT2B4 mRNA expression in 
human liver exceeds that of UGT2B7 9-fold (Ohno and Nakajin, 2009). Collectively, these data 
suggest a significant, perhaps major, contribution of UGT2B4 to human liver microsomal COD 
glucuronidation. This contrasts to the very minor or negligible contribution of UGT2B4 to AZT 
and morphine (3- and 6-) glucuronidation (Court et al., 2003; JO Miners, unpublished data). 
However, data of the competitive inhibition and a significant correlation of the rates of COD 
glucuronidation and the selective substrates of UGT2B4 and UGT2B7 in pooled HLM should be 
investigated in further study to confirm a significant contribution of UGT2B4. 
Drugs previously identified as potential UGT2B7 inhibitors in either in vitro or 
in vivo studies (viz. FLZ, KTM, KTZ and VPA) were screened for inhibition of human liver 
microsomal COD glucuronidation. IC50 values generated for FLZ, KTM, and KTZ in the presence 
of BSA were in the ranges of plasma and/or hepatic input concentrations observed for therapeutic 
doses in vivo. Thus, Ki values were determined for these compounds. As with the IC50’s, Ki values 
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generated from incubations supplemented with BSA (and corrected for binding to HLM and 
albumin) were 6.6- to 17-fold lower than the corresponding parameters determined in the absence 
of BSA. A similar effect of BSA was observed in studies of the FLZ - AZT and VPA – LTG 
interactions in vitro (Rowland et al., 2006; Uchaipichat et al., 2006a) and confirm that, like the 
Km, Ki values for UGT2B7 inhibitors are overestimated when BSA is not present in incubations of 
HLM.  
Ki values obtained here for FLZ (from incubations with and without BSA) 
inhibition of human liver microsomal COD glucuronidation were approximately 30% higher than 
the corresponding Ki reported for inhibition of AZT glucuronidation (Uchaipichat et al., 2006b). 
Moreover, the Ki value determined here for KTZ inhibition of COD glucuronidation also differs 
from inhibition studies with the predominantly UGT2B7 substrate morphine, which reported less 
potent inhibition (Takeda et al., 2006). While this may be due in part to the differing contributions 
of UGT2B4 and UGT2B7 to COD and morphine (3- and 6-) glucuronidation, binding to HLM 
was not accounted for in the morphine inhibition studies and  effects of BSA were not 
investigated. Inhibition of human liver microsomal morphine glucuronidation by KTM has been 
recently investigated (Miners JO; unpublished data). The reported Ki value for KTM inhibition of 
morphine-6-glucuronide formation in the absence and presence of 2% BSA were 35 and 5 μM, 
respectively which is consistent with the Ki values obtained from this study. 
Based on total inhibitor concentration in blood, extrapolation of the Ki values for 
FLZ, KTM and KTZ predicted 1.60, 1.10 and 2.97 fold increases, respectively in the AUC ratio 
for COD when co-administered with each inhibitor at the doses shown in Table 3.7. When 
considered in terms of unbound inhibitor concentration in blood, the inhibition potential of FLZ 
and KTM was unaltered. Although there is no consensus whether DDI potential should be 
predicted based on total or unbound concentration of the perpetrator drug in plasma, optimum 
predictivity of the magnitude of inhibitory interactions involving both CYP and UGT substrates is 
achieved when total maximum hepatic input concentration is employed in equation 2.8(Ito and 
Houston, 2004; Brown et al., 2005; Rowland et al., 2006; Uchaipchat et al., 2006b; Miners et al., 
2010). According to Ito and colleague (2004), various inhibitor concentrations calculated for use 
in the prediction of in vivo drug–drug interactions showed that the total hepatic input 
concentration of inhibitor together with in vitro Ki values is the most successful method for 
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identifying inhibitory DDIs. On this basis, significant DDIs involving inhibition of COD 
glucuronidation by FLZ, KTM and KTZ would be predicted in vivo.  
Like the prediction of DDI potential, IV-IVE may be employed to determine in 
vivo CLH and extraction ratio from the experimentally measured microsomal intrinsic clearance, 
calculated as CLint = Vmax/Km (see Miners et al., 2006 and 2010 for approach). Estimates of CLH 
for COD clearance via hepatic glucuronidation were derived with the equation for the well stirred 
model of the CLH using scaling factors given in Rowland et al. (2008b), 0.93 as the fraction of 
COD unbound in blood, and the mean Km and Vmax values generated here for human liver 
microsomal COD glucuronidation. The predicted CLH values were 0.82 L/hr and 5.74 L/hr for 
kinetic constants obtained in the absence and presence of BSA, respectively. The approximate 7-
fold increase in predicted CLH from in vitro CLint values determined from incubations 
supplemented with BSA is consistent with previous studies kinetic studies of UGT1A9, UGT2B7 
and CYP2C9 substrates conducted in this and other studies (Rowland et al., 2007; 2008a and b; 
Kilford et al., 2009). Despite this, the predicted CLH from experiments performed in the presence 
of BSA still under-predicts the known in vivo CLH for COD via glucuronidation (ca. 36 L/hr). 
The data are consistent with the 2- to 5- fold under-prediction observed for the predicted in vivo 
clearances of UGT2B7 substrates from in vitro data obtained in the presence of BSA (Rowland et 
al., 2007; Kilford et al., 2009), but contrasts to the near exact prediction of in vivo CLH for the 
UGT1A9 substrate propofol and the CYP2C9 substrate phenytoin when in vitro kinetic data 
generated in the presence of BSA are used for IV-IVE (Rowland et al., 2008 and b). Since it is 
believed that the Km value obtained from experiments with HLM supplemented with BSA reflects 
‘true’ hepatocellular Km (Rowland et al., 2007), other factors such as under-prediction of Vmax, 
extra-hepatic glucuronidation or uptake barriers presumably contribute to the accuracy of in vivo 
clearance prediction for moderately polar UGT2B7 substrates. 
In addition, this work showed a complex kinetic interaction between UGT2B7 
substrates. In both the absence and presence of BSA, addition of VPA changed the kinetics of 
C6G formation from the Michaelis-Menten or weak substrate inhibition to sigmoidal kinetics with 
increasing of Km (or S50) values by approximately 4.8- to 7.7-fold. This data was consistent with 
the existence of two “catalytic” sites for AZT, 4-MU, and 1-NP within the UGT2B7 substrate 
binding domain (Uchaipichat et al., 2008). The inhibition mechanism was a competitive 
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inhibition, as evidenced by decreased substrate binding affinity (i.e., increased Km or S50) without 
a change in Vmax. In addition, however, the observation of sigmoidal kinetics in the presence of 
VPA suggests the existence of cooperative binding of the second substrate molecule occurring in 
the presence of VPA. It is further assumed that VPA binds to a distinct effector site, which results 
in the complex C6G glucuronidation kinetics observed in the presence of modifier. 
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CHAPTER 5 
CONCLUSIONS 
In summary, IV-IVE predicts significant DDIs arising from inhibition of COD 
metabolic clearance via glucuronidation by coadministered FLZ and KTZ, but not KTM. 
Available evidence is generally consistent with superior pain relief from COD in CYP2D6 EMs, 
and absent or minor COD analgesia in PMs (Somogyi et al., 2007). Conversely, the relative 
conversion of COD to morphine is approximately 2 to 3-fold higher in CYP2D6 UMs compared 
to EMs and this may result in an exaggerated response, including sedation and respiratory 
depression. Thus, it may be speculated that inhibition of COD glucuronidation by coadministered 
drugs, for examples FLZ and KTZ, will potentially result in enhanced and prolonged analgesia 
due to increased formation of morphine. Furthermore, marked inhibition of the glucuronidation of 
high dose COD could conceivably result in morphine and COD toxicity. In addition, this work 
showed a complex kinetic interaction between UGT2B7 substrates. The observation of sigmoidal 
kinetics in the presence of VPA suggests the existence of cooperative binding of the second 
substrate molecule occurring in the presence of VPA. It is further assumed that VPA binds to a 
distinct effector site, which results in the complex C6G glucuronidation kinetics observed in the 
presence of modifier. 
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